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Preface 
 
 
The studies described in this thesis comprise work performed at the Fetal Medicine Units 
of King's College Hospital and Medway Maritime Hospital (United Kingdom). The project 
was guided by Professor Kypros Nicolaides and funded by The Fetal Medicine 
Foundation.  
 
According to "Artigo 4º, Diário da República, 2ª série, N.º 111, 9th June 2015 
(Regulamento n.º 320/2015)" and "Artigo 19º, Diário da República, 2ª série, nº 153, 7th 
August 2015 (Regulamento n.º 519/2015)", the results presented and discussed in this 
thesis were published in the following scientific peer-reviewed journals:  
 
• Fadigas C, Saiid Y, Gonzalez R, Poon LC, Nicolaides KH. Prediction of small-for-
gestational-age neonates: screening by fetal biometry at 35-37 weeks. Ultrasound 
Obstet Gynecol. 2015 May;45(5):559-65. doi: 10.1002/uog.14816. Epub 2015 Apr 9. Impact 
factor: 5.654. Cited by 29 (Google Scholar, 28 Jan 2019). 
 
• Fadigas C, Guerra L, Garcia-Tizon Larroca S, Poon LC, Nicolaides KH. Prediction of 
small-for-gestational-age neonates: screening by uterine artery Doppler and mean 
arterial pressure at 35–37weeks. Ultrasound Obstet Gynecol. 2015 June;45(6):715–721. 
doi: 10.1002/uog.14847. Epub 2015 May 4. Impact factor: 5.654. Cited by 15 (Google 
Scholar, 28 Jan 2019). 
 
• Fadigas C, Peeva G, Mendez O, Poon LC, Nicolaides KH. Prediction of small-for-
gestational-age neonates: screening by placental growth factor and soluble 
fms-like tyrosine kinase-1 at 35-37 weeks. Ultrasound Obstet Gynecol. 2015 
Aug;46(2):191-7. doi: 10.1002/uog.14862. Epub 2015 Jun 18. Impact factor: 5.654. 
Cited by 13 (Google Scholar, 28 Jan 2019). 
 
 
Partial results of this thesis were presented at international congresses, as part of a wider 
project, also lead by Prof. Kypros Nicolaides and funded by the Fetal Medicine 
Foundation. The referred research project aims to predict appropriate timing for third 
trimester growth scan, contingent to the second trimester scan. The meetings were the 
following: 
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• Poon C, Lesmes C, Bakalis S, Fadigas C, Nicolaides KH. Prediction of Fetal 
Growth Restriction. Advances in Fetal Medicine Course 2014, London, United 
Kingdom, 6-7 Dec 2014. [Oral presentation] 
 
• Poon C, Lesmes C, Bakalis S, Fadigas C, Nicolaides KH. Small for gestional age: 
Timing for 3rd trimester scan. 14th World Congress in Fetal Medicine, Crete, 
Greece, 21-25 Jun 2015. [Oral presentation] 
 
• Poon C, Gallo D, Bakalis S, Fadigas C, Nicolaides KH. Contingent model for the 
prediction of delivery of small-for-gestational-age neonates. 26th World Congress 
on Ultrasound in Obstetrics and Gynecology, Rome, Italy, 24-28 September 2016 
[Oral presentation]. Abstract available in Ultrasound in Obstetrics and Gynecology, 48, 
Suppl 1:2, September 2016. DOI: 10.1002/uog.16029. 
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Abstract 
 
 
Small for gestational age (SGA) is common in pregnancy and it has been associated with 
an increase in adverse perinatal outcomes, predisposition for neurological and cognitive 
delay in childhood and cardiovascular and endocrine diseases in adulthood.  
 
The classification is not consensual, having been defined in different studies as estimated 
fetal weight, abdominal circumference or birthweight below the 10th, 5th or 3rd percentiles, 
with the prevalence varying with the definition that is used.  
 
The increased risk of perinatal mortality and morbidity can be substantially reduced in 
cases identified prenatally, as close monitoring, timely delivery and prompt neonatal care 
can be undertaken, in comparison to those cases detected after birth. 
 
Over time, several screening methods have been introduced, in order to optimize the 
detection rate for SGA. These approaches range from abdominal palpation, symphyseal-
fundal height measurement, fetal biometries, uterine artery doppler assessment and, more 
recently, biochemical markers. 
 
The aim of this thesis is to develop a model for prediction of SGA neonates in the absence 
of pre-eclampsia, based on maternal characteristics, clinical history, fetal biometry, uterine 
pulsatility index (Ut PI), mean arterial blood pressure (MAP) and serum biochemical 
markers (serum placental growth factor: PlGF; Soluble fms-like tyrosine kinase-1: sFlt-1) 
at 35-37 gestational weeks. 
 
This was a prospective screening project for detection of SGA neonates, in women 
attending for their third-trimester hospital visit in pregnancy at King's College Hospital 
(London) and Medway Maritime Hospital (Kent). The project comprised three studies.  
 
The first study included biophysical measurements of 5515 pregnant women, including 
278 that delivered SGA (<5th) neonates. A SGA predictive model was developed based on 
the combination of maternal factors, clinical history and estimated fetal weight. 
 
In the second study, a subset of 5121 pregnant women was evaluated, 245 of which had 
SGA (<5th) newborns. A model was developed based on the combination of maternal 
factors, clinical history, estimated fetal weight, mean arterial pressure and uterine artery 
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dopplers. It was found that the additional use of mean arterial pressure and pulsatility 
index of the uterine arteries did not significantly improve the performance of screening for 
delivery of SGA neonates in comparison to the first study. 
 
In the third study, a subset of 3859 pregnant women was evaluated, comprising 158 SGA 
newborns. The SGA prediction model combined the following parameters: maternal 
factors, estimated fetal weight and biochemical values (serum placental growth factor, 
PlGF; fms-like soluble tyrosine kinase-1, sFlt-1). It was found that sFlt-1, when combined 
with maternal factors and fetal biometries, did not remain an independent factor in this 
predictive model. Additionally, serum PlGF only marginally improved the SGA screening  
performance when compared to the model of the first study. 
 
Hence, based on the findings, the best prediction was provided by the combination of 
maternal factors, estimated fetal weight and serum placental growth factor (PlGF). This 
combined screening predicted, at a 10% false positive rate, 88, 96 and 94% of SGA 
neonates with birth weight below the 10th, 5th and 3rd percentiles delivering at <2 weeks 
following assessment. The respective values for SGA delivering ≥37 weeks were 64, 75 
and 80%. 
 
In conclusion, combined screening by maternal factors, biophysical and biochemical 
markers at 35-37 weeks can identify a high percentage of pregnancies that will deliver 
SGA neonates. 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Small-for-gestational age; Late third trimester screening; Fetal biometry; 
Placental growth factor; Soluble fms-like tyrosine kinase-1. 
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Resumo 
 
Ser leve para a idade gestacional (LIG) é comum na gravidez e tem sido associado a um 
aumento nos resultados perinatais adversos, predisposição para défices neurológico e 
cognitivo na infância e doenças cardiovascular e endocrinológica na vida adulta.  
 
A classificação não é consensual, tendo sido definida em diferentes estudos como peso 
fetal estimado, circunferência abdominal fetal ou peso à nascença abaixo dos percentis 
10, 5 ou 3. Deste modo, a prevalência de LIG varia com a definição utilizada.  
 
O aumento do risco de mortalidade e morbilidade perinatal pode ser substancialmente 
reduzido nos casos identificados no período pré-natal, uma vez que a vigilância apertada 
da gravidez, com programação do parto na altura adequada e um atendimento neonatal 
apropriado podem ser oferecidos, em comparação com os casos apenas detectados 
após o parto. 
 
Ao longo do tempo, vários métodos de triagem foram introduzidos, a fim de optimizar a 
taxa de detecção de LIG. Essas abordagens incluem a palpação abdominal, a medição 
da altura uterina, a avaliação da biometria fetal, a medição dos dopplers das artérias 
uterinas e, mais recentemente, a utilização de marcadores bioquímicos. 
 
O objectivo desta tese é desenvolver um modelo para previsão de recém-nascidos LIG 
na ausência de pré-eclâmpsia, baseado em factores maternos, história clínica, biometrias 
fetais, índice de pulsatilidade das artérias uterinas, pressão arterial média e marcadores 
bioquímicos (factor de crescimento placentário sérico: PlGF; FMS-like tirosina cinase 
solúvel-1: sFlt-1) às 35-37 semanas de gestação. 
 
Este foi um trabalho prospectivo de rastreio de gestações simples às 35-37 semanas 
gestacionais, que decorreu no Reino Unido, no King's College Hospital em Londres e no 
Medway Maritime Hospital em Kent. O projecto foi organizado em 3 estudos distintos. 
 
No primeiro estudo foram incluídas medidas biofísicas de 5515 gestantes, em que 278 
grávidas tiveram recém-nascidos LIG (<p5) e foi desenvolvido um modelo de previsão de 
LIG com base na combinação de factores maternos, história clínica e peso fetal estimado.  
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No segundo estudo avaliou-se um subgrupo de 5121 gestantes, das quais 245 tiveram 
recém-nascidos LIG (<p5) e desenvolveu-se um modelo com base na combinação dos 
factores maternos, história clínica, peso fetal estimado, pressão arterial média e 
fluxometria das artérias uterinas. Constatou-se que a utilização adicional da pressão 
arterial média e do índice de pulsatilidade das artérias uterinas não melhorou 
significativamente a taxa de detecção de recém-mascidos LIG face ao primeiro estudo. 
 
No terceiro estudo, avaliou-se um subconjunto de 3859 grávidas, incluindo 158 recém-
nascidos LIG. O modelo de previsão de recém-nascido LIG combinou os seguintes 
parâmetros: factores maternos, peso fetal estimado e valores bioquímicos (factor de 
crescimento placentário sérico, PlGF; fms-like tirosina cinase solúvel-1, sFlt-1).  
Verificou-se que o sFlt-1, quando combinado com os factores maternos e biometrias 
fetais, não permaneceu como um factor independente neste modelo de previsão. 
Adicionalmente, observou-se que o PlGF sérico apenas melhorou marginalmente a taxa 
de detecção de LIG face ao modelo do primeiro estudo. 
 
Assim, dos vários modelos avaliados, aquele com melhor taxa de detecção de recém-
nascidos LIG foi fornecido pela combinação de factores maternos, peso fetal estimado e 
factor de crescimento placentário sérico (PlGF). Este modelo previu, com uma taxa de 
falsos positivos de 10%, 88, 96 e 94% dos recém-nascidos LIG com peso ao nascer 
inferior aos percentis 10, 5 e 3, respectivamente, e que nasceram <2 semanas após a 
avaliação em consulta. A taxa de detecção para LIG com nascimento ≥37 semanas foi de 
64, 75 e 80%.  
 
Em conclusão, o rastreio pelo modelo combinado de factores maternos, marcadores 
biofísicos e bioquímicos às 35-37 semanas pode identificar uma percentagem elevada de 
gestações com recém-nascidos LIG. 
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Figure Legends 
 
Figure 1.1 - Risk assessment for SGA as set out by the RCOG. 
Figure 3.1. Z-scores for fetal head circumference (a), abdominal circumference (b), femur 
length (c) and estimated fetal weight (d) at 35-37 weeks. 
Figure 3.2. Receiver-operating characteristic curves of maternal characteristics (black 
line), combination of maternal characteristics of HC, AC and FL z-score (blue line) and the 
combination of maternal characteristics with EFW z-score (red line) at 35-37 gestational 
weeks in the prediction of SGA with BW below the 10th (a), the 5th (b) and the 3rd (c) 
percentile, delivering < 2 weeks following assessment (left) or ≥37 weeks' gestation. 
Figure 4.1 Log10 uterine artery pulsatility index (UtA-PI) (a,b) and log10 mean arterial 
pressure (MAP) (c,d) multiples of median according to assessment-to-delivery interval 
(a,c) and birth-weight Z‐score (b,d) in pregnancies delivering small-for-gestational-age 
neonates with birth weight < 5th percentile, plotted on the 50th (solid line), 90th and 
95th (dashed line) percentile of the appropriate normal range. 
Figure 4.2. Receiver–operating characteristics curves of maternal factors (black) and 
maternal factors with uterine artery pulsatility index (red), mean arterial pressure (blue), 
estimated fetal weight Z‐score (green) and their combination (purple), at 35–37 weeks' 
gestation, in the prediction of small-for-gestational-age neonates with birth 
weight < 10th (a), < 5th (b) or < 3rd (c) percentile, delivering < 2 weeks following assessment 
(top) or ≥ 37 weeks' gestation (bottom). 
Figure 5.1. Log10 placental growth factor (a) and log10 soluble fms-like tyrosine kinase-1 
(b) multiples of the median (MoM) according to assessment-to-delivery interval in 
pregnancies delivering small-for-gestational-age neonates with birth 
weight < 5th percentile, plotted on the 50th (solid line) and 10th (dashed line) percentile of 
the normal range. 
Figure 5.2. Receiver–operating characteristics curves of maternal factors (black line), 
maternal factors with estimated fetal weight (EFW) (blue line), maternal factors with EFW 
and placental growth factor (red line) at 35–37 weeks' gestation, in the prediction of small-
for-gestational-age neonates with birth weight < 10th (a), < 5th (b) and < 3rd (c) percentile, 
delivering within 2 weeks of assessment. 
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Figure 5.3. Receiver–operating characteristics curves of maternal factors (black line), 
maternal factors with EFW (blue line), maternal factors with EFW and placental growth 
factor (red line) at 35–37 weeks' gestation, in the prediction of small-for-gestational-age 
neonates with birth weight < 10th (a), < 5th (b) and < 3rd (c) percentile, delivering 
≥ 37 weeks' gestation. 
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Table Legends 
 
Table 1.1. Common causes of growth restriction (Sankaran et al45) 
Table 1.2.  Birthweight comparison (in grams) based on standard mother being defined as 
of European origin, height 163 cm, weight 64 kg, first pregnancy, with baby sex averaged 
between male and female (Gardosi et al31)  
Table 1.3. RCOG risk factors for SGA fetus/neonate from history at booking (Robson et 
al, 2013). 
Table 1.4. RCOG risk factors for SGA fetus/neonate from current pregnancy 
complications (Robson et al9) 
Table 1.5. Studies showing the differences in PlGF in normal and pregnancies delivering 
a SGA neonate.  
Table 1.6. Studies showing the differences in sFlt-1 in normal and pregnancies delivering 
a SGA neonate.  
Table 1.7. Difference in PlGF/sFlt-1 ratio in normal and pregnancies delivering a SGA 
neonate 
Table 3.1. Characteristics of the study population of women with a singleton pregnancy 
with normal outcome or with a small-for-gestational age (SGA) neonate, in the absence of 
pre-eclampsia (PE). 
Table 3.2. Pearson correlation between Z-score values of head circumference, abdominal 
circumference, femur length and estimated fetal weights at 35-37 weeks’ gestation in the 
normal and small for gestational age groups. 
Table 3.3. Fitted regression model with maternal characteristics and history for the 
prediction of small for gestational age with birth weight below the 5th percentile, in the 
absence of preeclampsia. 
Table 3.4. Fitted regression models with maternal characteristics and history, fetal head 
circumference (HC) Z-score, abdominal circumference (AC) Z-score, femur length (FL) Z-
score or estimated fetal weight (EFW) Z-score at 35–37 weeks’ gestation, for the 
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prediction of small-for-gestational age with birth weight < 5th percentile, in the absence of 
pre-eclampsia 
Table 3.5. Performance of screening for small for gestational age (SGA) neonates with 
birthweight <10th, <5th and <3rd percentiles, delivering within 2 weeks of assessment and 
≥ 37 weeks' gestation, in the absence of pre-eclampsia, using maternal characteristics 
and history, fetal biometry or estimated fetal weight at 35-37 weeks' gestation 
Table 3.6. Detection rates (DR) in screening for small-for-gestational-age neonates with 
birth weight < 10th, < 5th and < 3rd percentile, delivering within 2 weeks of assessment, in 
the absence of pre-eclampsia, using maternal characteristics and history, fetal biometry or 
estimated fetal weight at 35–37 weeks’ gestation 
Table 3.7. Detection rates (DR) in screening for small-for-gestational-age neonates with 
birth weight < 10th, < 5th and < 3rd percentile, delivering ≥ 37 weeks’ gestation, in the 
absence of pre-eclampsia, using maternal characteristics and history, fetal biometry or 
estimated fetal weight at 35–37 weeks’ gestation 
Table 4.1. Characteristics of the study population of women with a singleton pregnancy 
with normal outcome or with a small-for-gestational age (SGA) neonate, in the absence of 
pre-eclampsia (PE). 
Table 4.2. Uterine artery pulsatility index (UtA-PI) and mean arterial pressure (MAP) at 
35–37 weeks’ gestation in pregnancies that delivered small-for-gestational-age (SGA) 
neonates with birth weight < 5th percentile, in the absence of pre-eclampsia, and in 
unaffected pregnancies 
Table 4.3. Fitted regression models with maternal characteristics and history, estimated 
fetal weight (EFW) Z-score, uterine artery pulsatility index (UtA-PI) and mean arterial 
pressure (MAP) at 35–37 weeks’ gestation for the prediction of small-for-gestational-age 
neonates with birth weight < 5th percentile, in the absence of pre-eclampsia 
Table 4.4. Performance of screening for small for gestational age neonates with birth 
weight <10th, <5th and <3rd percentile delivering within two weeks of assessment and at 
>37 weeks’ gestation, in the absence of preeclampsia, with maternal factors, estimated 
fetal weight, uterine artery pulsatility index and mean arterial pressure at 35-37 weeks’ 
gestation.  
Table 4.5. Detection rates (DR) in screening for small-for-gestational-age (SGA) neonates 
with birth weight < 10th, < 5th and < 3rd percentile, delivering within 2 weeks of assessment, 
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in the absence of pre-eclampsia, using maternal factors, estimated fetal weight (EFW), 
uterine artery pulsatility index (UtA-PI) and mean arterial pressure (MAP) at 35–37 weeks’ 
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pulsatility index (UtA-PI) and mean arterial pressure (MAP) at 35–37 weeks’ gestation 
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with normal outcome or with a small-for-gestational-age (SGA) neonate, in the absence of 
pre-eclampsia (PE) 
Table 5.2. Placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) at 
35-37 weeks’ gestation in small for gestational age (SGA) neonates with birth weight 
below the 5th percentile, in the absence of preeclampsia and in the normal group. 
Table 5.3. Fitted regression models with maternal characteristics and history (maternal 
factors), estimated fetal weight (EFW) Z-score, placental growth factor (PlGF) and soluble 
fms-like tyrosine kinase-1 (sFlt-1) at 35–37 weeks’ gestation for the prediction of small-for-
gestational-age neonates with birth weight < 5th percentile, in the absence of pre-
eclampsia 
Table 5.4. Performance of screening for small-for-gestational-age (SGA) neonates with 
birth weight < 10th, < 5th and < 3rd percentile delivering within 2 weeks of assessment, in 
the absence of pre-eclampsia, using maternal characteristics and history, estimated fetal 
weight (EFW), placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-
1) at 35–37 weeks’ gestation. 
Table 5.5. Performance of screening for small for gestational age (SGA) neonates with 
birth weight <10th, <5th and <3rd percentile delivering at >37 weeks’ gestation in the 
absence of preeclampsia, with maternal characteristics and history, estimated fetal 
weight, placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) at 
35-37 weeks’ gestation. 
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Chapter 1. Introduction 
 
1.1. DEFINITION AND EPIDEMIOLOGY OF SMALL FOR GESTATIONAL AGE AND FETAL GROWTH 
RESTRICTION 
 
Small for gestational age (SGA) is usual in pregnancy1. It is associated with increased 
adverse perinatal outcomes2, predisposition for neurological and cognitive delay in 
childhood and cardiovascular and endocrine diseases in adulthood3, 4.The classification is 
not consensual and the prevalence will vary with the definition that is used.  
 
Historically, a birthweight (BW) below 2500g and, occasionally, under 1500g, was used as 
a cut-off for the definition of SGA. The World Health Organization still uses the definition 
of SGA as neonatal weight below 2500g at term5. This definition is especially useful in 
developing countries, as it eliminates the impact of accurate pregnancy dating and since 
low birthweight has long been used as an important public health indicator.  
 
However, with the introduction of population based gestational age dependent BW charts 
since Lubchenco6, there was a move to the use of percentiles, which has been widely 
adopted in developed countries. The definition of SGA is not consensual and various 
cut-off limits have been proposed, including estimated fetal weight (EFW), BW, abdominal 
circumference (AC) or, more recently, BW charts comprising babies still in utero7 below 
the 10th, 5th or 3rd percentiles or -2 standard deviations (SD) below the mean for 
gestational age. The ideal cut-off remains uncertain.  
 
The differentiation between constitutionally small and fetal growth restriction (FGR) and 
the subsequent obstetric management is challenging. The distinction is important, since 
SGA fetus have a good prognosis compared to FGR fetus. Some authors use the terms 
SGA and FGR interchangeably, although the majority of SGA are constitutionally small. 
FGR suggests an underlying pathology and refers to a fetus that has failed to achieve its 
optimal growth potential 8, 9. It affects up to 5-10% of all pregnancies10. Fetus with a BW 
below the 10th percentile may not be growth restricted, but rather constitutionally small. 
The incidence of FGR and SGA are approximately 10%11, 12. Although they are not the 
same population, there is an overlap, as FGR concentrates in the SGA population. Using 
the 10th percentile as cut-off, it is estimated that in the SGA population, 40% neonates are 
constitutionally small and 60% are growth restricted12, 13. The lower the weight percentile, 
the higher the chances of pathology and, thus, growth restriction and problems after birth. 
Lowering the threshold for SGA, increases the likelihood of the fetus being fetal growth 
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restricted and lowers the false positive rate (FPR)14. Nevertheless, this definition fails to 
recognize the fetus that have fallen across the percentiles, but still remain above the 10th 
percentile14.  
 
The challenge is to differentiate constitutionally SGA from FGR fetus and to define FGR 
fetuses in the group of appropriate for gestational age (AGA) or large for gestational age 
(LGA). The risks of inaccurate definition of FGR within these different growth groups are 
overtreatment of healthy SGA and undertreatment of FGR fetus with normal growth.  
 
The traditional approach for identifying pregnancies with SGA fetuses by maternal 
abdominal palpation and serial measurements of symphisis-fundal height has a detection 
rate of 30-85%15-21, as obesity and leyomiomas limit its accuracy. 
 
A few studies comprising low-risk singleton pregnancies have examined the potential 
value of sonographic fetal biometry during the third trimester in the prediction of SGA 
neonates 22-28.Of these, only one study27, up until the end of the studies of this thesis, 
examined the value of EFW in a late third trimester-ultrasound examination in low risk 
pregnancies 
 
The use of mathematical models, as well as customized charts10 adjusted for 
physiological variables, might improve the classification of fetal growth. They would help 
to identify fetuses that are small because of constitutional reasons and not because of 
FGR, reducing unnecessary investigations and interventions 29-32. 
 
The advantage of serial ultrasound examinations for longitudinal growth assessment has 
not been clearly demonstrated33, 34.  
 
Doppler studies of maternal and fetal circulation have also shown to improve the 
diagnosis of SGA and FGR, as often SGA have normal doppler studies, whereas FGR 
show doppler abnormalities, due to placental insufficiency35.  
 
Histological studies report that in preeclampsia (PE) and SGA without PE there is 
impaired placentation, with inadequate trophoblastic invasion of the maternal spiral 
arteries. This leads to an altered placental production and systemic release of 
antiangiogenic (soluble fms-like tyrosine kinase-1: sFlt-1) and proangiogenic (placental 
growth factor: PlGF) factors36. Several studies, mainly case-control, reported that, in 
pregnancies delivering SGA neonates, maternal PlGF is decreased and sFlt-1 is 
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increased, both in the second and third trimesters of pregnancy. This translates into an 
increase in the sFlt-1/PlGF ratio37-39, which is not as high in late-onset FGR as in early 
onset FGR37, 40. There has been a positive correlation in between sFlt-1/PlGF ratio and the 
likelihood of complications41, 42.  
 
 
 
1.2. ETIOLOGY AND PATHOPHYSIOLOGY OF GROWTH RESTRICTION 
 
 
At a cellular level, fetal growth has three different stages 43: 
• 0-16 weeks: Hyperplasia 
• 16-30 weeks: Hyperplasia and hypertrophy  
• 30 week - term: Hypertrophy 
 
An exponential curve translates fetal growth between the end of the first trimester and the 
last part of the third trimester, with only a slight tailing off around term. However, if we 
consider the percentage of mass gained per week rather than absolute mass gain, the 
greatest growth rate occurs in the early stages of pregnancy (in between conception and 
middle of second trimester), whilst organogesis occurs, in a period of very rapid cell 
division. From that point onwards, growth occurs mainly due to organs' maturation and 
hypertrophy44. 
 
Normal fetal growth relies on the coordination of several components, namely, the genetic 
growth potential of the fetus, the ability of the placenta to transfer nutrients and oxygen to 
the fetus and the capacity of the maternal body to deliver these nutrients to the placenta. 
All of which, are influenced by the surrounding environment44.  
 
Hence, the etiology of fetal FGR can be categorized into maternal, fetal, placental and 
environmental factors (Table 1.1)45. Even though the pathophysiology of the various 
underlying conditions is different, the majority of the cases will lead to sub-optimal 
placental perfusion and fetal nutrition1, 9. 
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                   Table 1.1: Common causes of growth restriction (Sankaran et al 45) 
Common causes for FGR 
Maternal factors 
 
• Undernutrition 
• Low maternal weight gain 
• Low maternal BW 
• Extremes of maternal age 
• Low socio-economic status 
• Nulliparity 
• Medical conditions (eg, pregestational diabetes, renal insufficiency, 
systemic lupus erythematosus, antiphospholid antibody syndrome, 
hypertensive disease pregestational or pregnancy-related, 
cyanotic cardiac disease) 
 
Environmental factors 
 
• Substance use and abuse (tobacco, alcohol, cocaine or narcotics) 
• Teratogen exposure 
• Daily vigorous exercise 
• High altitude (above 1500m) 
• Irradiation 
 
Fetal factors 
 
• Chromosomal abnormalities 
• Genetic diseases 
• Congenital malformations 
• Intrauterine infections 
• Multiple gestation 
 
Placental factors 
 
• Abnormal placentation 
• Chronic abruption, infarcts and focal lesions 
• Chronic inflammatory conditions 
• Chorioangioma 
• Single umbilical artery, velamentous cord insertion 
• Confined placental mosaicism 
 
 
 
 
1.2.1. Maternal factors 
 
Nutrition 
 
Animal studies have shown that both maternal undernutrition and overnutrition reduce 
placental-fetal blood flows and reduce fetal growth, by decreasing placental synthesis of 
nitric oxide (a major vasodilator and angiogenic factor) and polyamines (key regulators of 
DNA and protein synthesis). There is some evidence that maternal nutrition status can 
alter the epigenetic state of the fetal genome, which may provide a molecular mechanism 
for the impact of maternal nutrition on both fetal programming and genomic imprinting46.  
 
Studies of pregnant women during famine times have shown an association between SGA 
and maternal undernutrition. However, the American College of Obstetricians and 
Gynecologists (ACOG)47-49 reports that there is no high-quality evidence to support that an 
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additional nutrient intake will improve the outcome of FGR, in the absence of true 
malnutrition. 
 
 
Weight, height, body mass index and low maternal weight gain 
 
The median weight and the median height of women delivering an SGA fetus is lower than 
those delivering an AGA fetus50, 51. More often, the studies have assessed maternal 
characteristics on the basis of body mass index (BMI) and several of these have shown 
that the lower the BMI, the higher the risk of delivering a SGA neonate52, 53. 
 
Low maternal weight gain has been shown to be associated with SGA, even when 
adjusted for confounding factors as height, BMI, parity, race, toxemia and diabetes. The 
relative risk (RR) was 1.8 (95% CI, 1.3-2.6) in the second trimester and 1.7 (95% CI 1.3-
2.3) in the third trimester54. This increased risk was observed across the spectrum of 
maternal BMI54. Regardless, the Royal College of Obstetricians and Gynaecologists 
(RCOG)9  no longer recommends that women are routinely weighted during pregnancy as 
a form of screening for SGA. 
  
 
Low maternal birthweight 
 
Parental contribution for fetal birthweight through inherited genes is estimated to be 
around 30-70%55. Potential interaction in between fetal genes and uterine environment 
influences fetal size, with animal studies suggesting that growth is modified towards 
maternal size. In general, fetal growth tends to be restrained by maternal environment and 
this is more evident in the first pregnancy. This trace appears to be inherited through the 
maternal line, with several genes being potentially associated, namely mitochondrial DNA 
16189 variant and common variants of maternally only expressed genes, such as H19. 
Several other genes have been reported to be in association with SGA and FGR (insulin-
like growth factor IGF-1, IGF-2, G-protein beta 3 subunit, inducible cytochrome P450, 
genes encoding angiotensinogen, placental alkaline phosphatase and vitamin D 
receptor45, 56, 57. Paternally inherited genes seem to play a role when the maternal 
component of restraining fetal growth is less evident. With paternal birthweight history of 
SGA, a study58 reports a 3.47 fold increase risk of the fetus being SGA (95% CI, 1.17-
10.27) 
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Maternal age 
 
Extremes of maternal age have been associated with a higher risk of SGA.  
 
Women<17 years:  A study59 reports the highest incidence of SGA in mothers <17 years 
of age (3.2%). Nevertheless, young age did not remain as an independent risk factor, 
when it was adjusted to other maternal factors, such as race, education, parity, marital 
status and prenatal care. These results indicate that the higher incidence of SGA in 
younger mothers apparently reflects their poor sociodemographic and prenatal care 
status.  
 
Advanced maternal age: Women over 35 years are at higher risk of many pregnancy 
complications, mainly because they are more likely to have pre-existing medical 
conditions than their younger counterparts, predisposing them to develop pregnancy 
complications60. It was observed that women over 40 years of age were at increased risk 
of pregnancy complications and this risk persisted even when the data was adjusted for 
preexisting maternal disease61. Hence, maternal age 40 years or older constitutes a major 
risk factor for having a small-for-gestational-age neonate, with an odd ratio (OR) of 3.2 
(95% CI 1.9-5.4) having been reported62. 
 
 
Ethnicity 
 
It has been referred that birthweight is affected by ethnicity. Gardosi's study31 to assess 
the factors that affect fetal growth and birthweight in the population to derive the 
coefficients to obtain customized charts, shows that african babies can weight less than 
218g less than European babies, whereas Chinese babies can weight 100g more (Table 
1.2).   
 
Table 1.2 -  Birthweight comparison (in grams) based on standard mother being defined as of European origin, height 
163 cm, weight 64 kg, first pregnancy, with baby sex averaged between male and female (Gardosi et al 31)  
Ethnic origin United States England New Zealand Australia 
African American -161.0 — — — 
African Caribbean — -127.5 — — 
African — -218.5 — -297.4 
Hispanic -38.6 — — — 
Middle Eastern. — -89.9 — -110.0 
Bangladeshi — -79.3 — — 
Indian/Pakistani — — — -162.0 
Indian — -149.4 -149.5 — 
Pakistani — -187.3 — — 
Chinese — — 100.9 — 
Maori — — — -66.8 
Samoan — — — 84.2 
Tongan — — — 124.1 
Other -140.8 — — — 
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This also impacts on the incidence of SGA neonates. In 2008, the Office of National 
Statistics63 released its data on all deliveries in England and Wales from 2005. The data 
showed that babies born to white mothers were larger than those of south Asian or black 
mothers. Further dividing those two groups into Pakistani, Indian, Bangladeshi, African 
and Caribbean, showed that the lowest mean BW was in Bangladeshi mothers. However, 
the largest percentage of babies born either <2.5 kg or <1.5 kg was in the Caribbean 
group. Further United Kingdom (UK) studies, documented that Afro-Caribbean, South 
Asian, East Asian and mixed race women were statistically significantly more likely to 
deliver an SGA baby than white women50-51, 64. 
 
 
 
Parity 
 
Nulliparity - The biological mechanisms by which parity and SGA are correlated are not 
quite understood. Nulliparous women have significant associations with adverse 
outcomes, particularly, when women are also of young age (<18 years). A review65 has 
shown an association with term SGA and nulliparity. For nulliparous aged under 18 years, 
the adjusted odds ratio (aOR) was 1.80 (95% CI: 1.62-2.01)65. For nulliparous aged 18-34, 
the association was not as strong, but still significant, with aOR of 1.51 (95% CI: 1.39-
1.64)65. Several studies have hypothesized that in young mothers, maternal-fetal 
competition for nutrients and/or the mother’s incomplete physical growth might contribute 
to adverse neonatal outcomes65, 66. 
 
 
Grand Multiparity - Multiple studies have shown an association in between grand 
multiparous and medical, obstetric and placental complications. Biological mechanisms 
have been used to explain this association (eg: chronic hypertension for abruption or 
atrophy of the endometrium for placenta previa)65. A study67 reports that grand multiparity 
in an economically stable population is not a major risk factor and that previous studies 
reflect socio-economic factors and not parity itself. This was also shown in a meta-
analysis, where a higher risk of SGA was identified in the subgroup of less developed 
countries, whereas the increase in uterine blood flow associated with increasing 
multiparity leads to an higher BW in subsequent newborns65. 
 
 
 
  28 
Maternal medical conditions  
 
Medical conditions that are associated with vascular disease and interfere with utero-
placental circulation increase the risk of FGR. These include hypertensive disorders, 
pregestational diabetes, auto-immune diseases (eg: systemic lupus erythematosus - 
SLE), renal insufficiency and antiphospholid syndrome. As for hereditary thrombophilias 
(eg, factor V Leiden or prothrombin gene mutations), the association with FGR is not 
consistent1. The effects of placental underperfusion vary, whether the placental 
insufficiency has early or late onset. Early onset insufficiency leads to the 
underdevelopment of terminal villi, with terminal villous hypoplasia. Late onset 
insufficiency leads to advanced maturation of the villi, with increased capillary branching, 
which only compensates the degree of hypoxia temporarily45, 68. Where the maternal 
supply of the placenta has been completely occluded, there will be infarctation of the 
associated area. 
 
The risks of SGA associated with pathology that affect placental perfusion are significant. 
The adjusted relative risk (aRR) for chronic hypertension is 2.5 (95% CI 2.1-2.9) 69, being 
associated with the inadequate conversion of the spiral arteries in the decidua and 
myometrium. Diabetes with vascular disease has an OR of 6 (95% CI1.5-2.3)70, the 
underlying mechanism involving small ischaemic villi, immature/dysmature villi and 
inconsistent glucose supply to the fetus. For renal impairment, the aOR is 5.3 (95% CI 
2.8-10)71. SLE has an OR of SGA of 5.6 (95% CI 4.1-7-8)72. The presence of 
anticardiolipin antibodies gives a RR of SGA 6.22 (95% CI 2.42-16.0)73. 
 
 
 
Previous pregnancy history 
 
Having a previous SGA neonate, increases up until three-fold the risk of having another 
SGA, using a cut-off of BW below the 10th percentile (OR 3.9; 95% CI 2.14-7.12)9, 74. This 
risk is further increased, after two SGA deliveries75. The King’s College Group, in two 
prospective studies51, 64, showed, not only that women with a previous SGA neonate were 
more likely to deliver another SGA baby than those who had previous normal babies, but 
also that this risk remained significantly higher even if they had delivered a normal baby 
after an SGA baby.  
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Method of conception 
 
In comparison with naturally conceived children, singletons born after assisted 
reproductive technology (ART) have a higher risk of FGR and other adverse outcomes, 
with studies reporting a risk of 40-60% of SGA in ART neonates61, 76. Regarding singleton 
pregnancies after in vitro fertilization (IVF), a review76 reports an OR of 1.59 for SGA (OR 
1.59; 95% CI 1.20-2.11). The results were in consistency with a meta-analysis77, which 
reported an OR of 1.8 (95% CI 1.4, 2.2) for low birth weight (<2500g), an OR of 2.7 (95% 
CI 2.3, 3.1) for very low birth weight (<1500g) and an OR of 1.6 (95% CI 1.3, 2.0) for small 
for gestational age (<10th percentile). Nevertheless, according to a study78, the increased 
risk of SGA observed among infertile couples, with or without infertility treatment, 
suggests that infertility may be a risk factor itself for FGR. 
 
 
1.2.2. Environmental factors 
 
Substance use and abuse 
 
Smoking tobacco, both active and passive exposures, leads to SGA through its hypoxic 
effect. A variety of factors has been considered, including poor nutritional state of the 
mother, toxins and carbon monoxide disruption of oxygen binding. The use during 
pregnancy has been associated with a 3.5 fold increase of SGA79. Further studies have 
shown that the risk is dose dependent, increasing with the number of cigarettes smoked. 
A study80 reported that women smoking up to 10 cigarettes per day have an OR of 1.54 of 
having a SGA fetus (95% CI, 1.39-1.70) and those who smoke more than 10 cigarettes 
have an OR of 2.21 (95% CI, 2.03-2.40). A Cochrane review81 of fifty-six randomised 
controlled trials (over 20,000 pregnant women) and nine cluster-randomised trials (over 
5000 pregnant women) has shown that smoking cessation interventions reduced low 
birthweight (RR 0.83, 95% CI 0.73 to 0.95). Another study82 indicated that stopping 
smoking prior to 15 weeks reversed the risk of SGA to that of a non smoker, showing aOR 
of SGA of 1.06 (95% CI 0.67-1.68) in women who stopped smoking by 15 weeks vs 1.76 
(96% CI 1.03-3.02) in those who kept smoking.  
 
Second and third trimester consumption of alcohol may result in SGA, with the impact 
being dose dependent83. A meta-analysis84 of 28 studies indicated an overall pooled RR of 
SGA of 1.12 (95% CI 1.04–1.20) for mothers drinking before or during pregnancy. 
However, this result was not significant when adjusted for confounders. The risk of SGA 
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only becomes apparent when the consuption of alcohol exceeds an average of one drink 
per day. The risk becomes two-fold for an average of four to five units per day, reaching a 
maximum RR of 7.48 (95% CI 4.46–12.55)84 for 12 units of alcohol per day. Conversely, 
consuming less than one drink per day has a minimal effect on intrauterine growth 
and birth weight84. 
 
Cocaine acts on the central nervous system and, through its sympathomimetic 
vasoconstritive effects, can cause hypertension in the mother and fetus, leading to infarcts 
or hemorrhages in the placenta, at any time in gestation. Due to its high water content, 
lipid solubility, low molecular weight, and low ionization at physiologic pH, it is believed 
that it crosses the placenta by simple diffusion85. Cocaine use during pregnancy is 
associated with SGA, with an OR of 3.66 (95% CI, 2.90-4.63)86. 
 
 
Teratogen exposure 
 
A variety of pharmacological substances has been implicated with FGR, with the 
teratogenicity being dependent not only on the substance itself, but also on the dosage, 
timing and duration of exposure and on the individual genetic predisposition1.  
 
 
 
Vigorous exercise 
 
Exercise is recommended in pregnancy. However, high intensity exercise is associated 
SGA, with an aOR of 3.3 (95% CI, 1.5-7.2%)87. The mechanism in uncertain, but it can be 
related with flow reduction in the uterine arteries during vigorous exercise88.  
 
 
 
1.2.3. Fetal factors 
 
Chromosomal abnormalities and genetic diseases 
 
Growth potential is adversely influenced by genetic disorders and chromosomal 
abnormalities. Genetic diseases affect the rate of cellular division, leading to poor growth 
early in pregnancy. This growth restriction will be enhanced in later stages of pregnancy. 
On the other hand, in fetus with chromosomal abnormalities, not only the rate of cell 
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division is reduced, but also placental development is affected, resulting in an additional 
factor of poor nutrient supply later in pregnancy44. 
 
 
Congenital malformations 
 
Fetus with congenital malformations (with a normal karyotype), are at an increased risk of 
being SGA. Gastroschisis is frequently associated with FGR, being up to 25% of these 
fetuses growth restricted1, 89. Congenital heart problems also are correlated to SGA, 
having being hypothesized that fetal hemodynamics impact on  suboptimal fetal growth1. 
 
 
 
Intrauterine infections 
 
Intrauterine infections are responsible for around 5-10% of FGR cases1. All the common 
bacterial, viral and protozoal infections have been associated with FGR. Cytomegalovirus, 
toxoplasmosis, rubeolla, varicella, syphilis and malaria are the infections most commonly 
involved with FGR, with the latter accounting for most of the cases of infection related 
FGR worldwide. Infections in pregnancy can affect fetal growth not only at a fetal cellular 
level, but also at a placental level, as inflammation and scarring of the placenta can 
interfere with nutrient supply1, 44. 
 
Multiple gestation 
 
The risk of SGA in multiple gestations is increased, having been reported as high as 25% 
in twin pregancies and reaching 60% for triplets and quadruplets1. The prevalence will 
vary, not only according to the number of fetus, but also in regard to chorionicity, as 
complications as twin-to-twin transfusion and selective fetal growth restriction tend to arise 
due to the uneven share of the placenta in monochorionic fetus.  
 
Fetal gender 
 
It has been shown that male fetuses and neonates have both an EFW and a BW larger 
than females. Thus, the risk of a female being considered SGA is higher90.  
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1.2.4. Placental factors 
 
 
Placenta is the interface between maternal and fetal circulation. The development of 
placental transport systems and the activation of endocrine and paracrine signaling 
pathways between the mother, the placenta, and the fetus, will eventually coordinate fetal 
growth.  
 
The blastocyst implantation triggers the development of the placental vasculature. The 
migration of the cytotrophoblast forms anchoring villi among the decidua and the uterus. 
At the same time, hypoxia-stimulated angiogenesis forms vascular connections between 
the maternal circulation and the intervillous space43, 68, 91. Fetal villous budding and 
trophoblastic invasion of the maternal spiral artery, promotes further nutrient, waste and 
gas exchange. 
 
Trophoblast-induced vascular adaptation induces an increase in the diameter of the spiral 
arteries from 15–20 to 300–500 mm during the second trimester92. This process is 
designated 'physiological changes of pregnancy', decreases the resistance to, and 
increases the volume of blood flow within the placenta. Hence, it optimizes fetal-maternal 
exchange in the intervillous space68, 91.  
 
Further growth of the placenta results in a term placental exhange area of 12 m2, with 
around 600 ml/min flow of maternal blood to be matched by 400 ml/kg/min of fetal flow. 
Once all the placental transport systems have been established, growth is determined by 
substrate availability, placental perfusion from the maternal circulation, transplacental 
paracrine and endocrine signaling, and the perfusion of the fetal placental compartment45. 
 
 
Abnormal placentation 
 
Abnormal placentation, with impaired placental vessels development, can lead to a 
reduction in fetal growth. The reduction in utero-placental blood flow can occur by a 
reduction in the number the following structures: normal villi at the fetal-maternal interface, 
arterioles in the tertiary stem villi, terminal capillary loops and villous tree elaboration44.  
 
  33 
The rate of DNA synthesis is decreased in the trophoblasts in FGR and the placental 
cotyledon's cross-sectional area is reduced. These findings are suggestive of alterations 
in placental development45. 
 
A small placenta has been associated with a small neonate93. However, this evidence is 
not consistent, as the placenta can hold up unto 30-40% functional inactivation of the 
villous population without affecting fetal growth94. Clinically, the severity of placental 
dysfuntion is assessed by Doppler ultrasound. Uterine artery (UtA) dopplers assess the 
maternal blood flow to the uterus and umbilical artery (UA) doppler assesses the response 
of the fetus to placental function. UA doppler resistance will only be raised when 
approximately 30% of the villous are affected43. That occurs due to the placenta's 
potential for compensatory growth43,45. 
 
 
Placental disorders 
 
Also, SGA can be caused by any factor that leads to a decrease in utero-placental 
transfer of nutrients, such as placental abruption, infarcts, haematomas or abnormalities 
(eg: chorioangioma)45. 
 
 
Umbilical cord abnormalities  
 
Single umbilical artery (SUA) is a common finding, which is found in nearly 1% of liveborn 
fetuses. Still, the association with SGA with isolated SUA (iSUA) is not consensual. 
Regardless, it is reported an almost two fold increased risk of FGR for iSUA, even after 
adusting for smoking, gestational diabetes, African-American race and pre-eclampsia 
(aOR 1.9, 95% CI 1.4-2.5)95. 
 
Regarding abnormal cord insertion (velamentous cord insertion - VCI; marginal cord 
insertion - MCI), in singleton pregnancies, it is stated that FGR neonates (BW<3rd 
percentile) are at higher risk for poor neurological outcomes. Namely, for cerebral palsy 
the OR is of 10.1 (95% CI 2.4-41.5) for VCI and 4.3 (95% CI 1.6-11.9) for MCI96. As for 
developmental disorders, the OR is of 6.7 (95% CI 1.7-26) for VCI96. Also, for SUA it is 
reported an increased risk for development problems, with an OR of 3.9 (95% CI 1.1-
14.2)96.  
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Confined placental mosaicism 
 
Confined placental mosaicism occurs in up to 2% of pregnancies57 and was found to be 
three times more common in SGA rather than in AGA fetus97.  
 
 
 
 
1.3. ADVERSE OUTCOMES OF SMALL FOR GESTATIONAL AGE 
 
In case of placental insufficiency, the fetus adjusts and adapts to the inadequate supply of 
nutrients, in order to optimize its chances of postnatal survival. The adaptive mechanism 
consists of several strategies, which lead to adjustment in fetal circulation, to spare the 
brain and the axial skeleton45. 
 
A catabolic state, with consumption of subtracts to provide energy, is the immediate 
response to malnutrition. If insufficient supply of nutrients persists, alterations in 
metabolism occur, which are mediated by changes in hormonal synthesis, such as a 
decrease the production of IGF-1 and the sensitivity of the tissues to it98. The initial 
response to late fetal growth restriction, does not necessarily translate into a weight 
change, but typically there is an increase in the brain-to-liver weight. This is followed by 
fetal adrenal hypertrophy, with increased glucocorticoid activity and a decrease in thymus 
weight. Further ahead, there will be a reduction in fetal growth and amniotic fluid, as well 
as myocardium hypertrophy99. If the compensatory mechanisms reach their limits, fetal 
distress occurs and, ultimately, there may be intrauterine demise45, 100. 
 
 
 
1.3.1. Impact of placental insufficiency on organ functions  
 
Brain 
 
Sparing mechanisms aim to compensate oxygen brain supply during hypotensive 
episodes. These mechanisms include an increased cerebral blood flow and a decreased 
metabolic rate, by electrophysiological and behavioral states changes101. However, in 
case of chronic placental insufficiency, it is uncertain whether these mechanisms of 
protection are enough to ensure enough oxygen supply45. 
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Cardiovascular 
 
In FGR, there is cardiac hypertrophy as a result of increased cardiac afterload. Also, there 
is a decreased cardiac output to the placenta. Both result in an increased recirculation of 
deoxygenated umbilical flow within the fetus. The shunting through the ductus-venosus is 
higher, with a reduction of the fraction of blood directed to the fetal liver102.  
 
 
Lungs 
 
In response to the increased levels of adrenocorticotrophic, there is accelerated lung 
maturation, as an adaptative mechanism, for increasing the chances of extra-uterine 
survival103. 
 
 
Skeletal muscle 
 
The DNA synthesis is reduced in skeletal muscle. Hence, growth-restricted fetus have a 
reduction in muscle mass, with a reduction in muscle fiber number, when compared with 
their appropriate grown counterparts. Muscle hypertrophy can only partially compensate 
for this limitation in fiber number104, 105.  
 
 
Gastrointestinal tract 
 
Reduction of the mesenteric blood flow can be associated with the poor nutrient 
absorption and postnatal intestinal motility syndrome, more frequently seen in FGR106. 
 
 
 
1.3.2. Adverse perinatal outcomes 
 
FGR is associated with stillbirth, neonatal death, cesarean section (CS) delivery for fetal 
distress, neonatal acidosis and neonatal unit admission1, 100, 107-110.  
 
The risk of stillbirth for SGA (EFW <10th) is of 1.5%, which is twice as high as reported for 
AGA1. This is consistent with the findings in one study100, which reported a higher 
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incidence of neonatal death  (1.1 vs 0.4/1000 births) in a cohort of uncomplicated term 
pregnancies with SGA (BW <10th percentile), with an aOR of 2.56 (95% CI, 1.83–3.57). 
The more severely affected the fetuses are, the higher the risk is1. 
 
It is also reported an association between SGA (BW<10th percentile) and hypoxic 
composite neonatal morbidity (5-minute Apgar score, hypoxic-ischemic encephalopathy, 
seizures and neonatal death)107. After adjusting for potential confounders, hypoxic 
composite neonatal morbidity was significantly higher in SGA (1.1%) compared with 
normally grown babies (0.7%), with an aRR of 1.44 (95% CI, 1.07–1.93)107. 
 
Another study showed that SGA (EFW<5th) had a higher risk of long neonatal hospital 
stay (RR 2.7; 95%, CI 2.3-7.8), neonatal unit admission (RR 3.2; 95% CI, 2.2-4.8) and 
stillbirth (RR 7.7; 9% CI 2.6-23)108. 
 
The higher risk for having a CS for SGA fetus (EFW<10th percentile) with normal dopplers 
was shown by Savchev et al109. The risk for CS due to fetal distress was higher (22.0 vs 
15.9%; p=0.21), but not the risk for intrapartum CS109. However, for fetus with EFW<3rd 
percentile, the risk was both higher for CS for fetal distress (25.0 vs 8.3%; p<0.01) and for 
intrapartum CS (30.0 vs 15.3%; p 0.04)109. 
 
In order to prevent potential adverse outcomes, it is important to identify SGA, as there is 
a four-fold increase of adverse fetal outcome (OR 4.1; 95% CI, 2.5-6.8) in SGA fetuses 
not recognised antenatally110. Breaking down the outcomes, considering SGA not 
identified antenatally vs SGA identified antenatally, the risks are higher for the first, with 
an aOR of 2.3 (95% CI, 0.8-6.6; not statistically significant) for cerebral damage, 4.5 (95% 
CI, 2.1-8.5) for severe fetal distress and 4.2 (95% CI, 2.1-8.5) for fetal/infant death110. In 
the same study, by comparing the SGA group with the AGA group, it was observed that 
the risk  for umbilical pH<7 (OR 2.3; 95% CI 1.5-9.8) and Apgar score<4 at 5 minutes (OR 
3.1; 95% CI, 1.8-5.4) was higher for the SGA fetuses110. 
 
 
1.3.3. Long-term adverse outcomes 
 
Intrauterine remodeling is a process that alters gene expression due to an intrauterine 
insult, leading to tissue hyperplasia, abnormal cell type balance or incorrect timing of gene 
induction. These changes, that are part of a survival strategy, not only have short-term 
impact, but also have long-term consequences45, 111. 
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It is described that FGR fetus have predisposition for neurological and cognitive delay in 
childhood and cardiovascular and endocrine diseases in adulthood 
 
 
Neurological and cognitive development 
 
The main long-term concern regardind SGA, is the neurodevelopment outcome. A small 
study112 showed that microstructural and metabolic brain changes are identifiable by fetal 
Magnetic Resonance Imaging (MRI) spectroscopy and diffusion weighted imaging at 37 
weeks in SGA fetuses. This suggests that the brain development of this population is 
different. 
 
A cohort113 was designed to assess term SGA infants, with normal dopplers. 
Neurobehavioral performance was evaluated at corrected age of 40 weeks, with the 
Neonatal Behavioral Assessment Scale (NBAS). The results showed that there was a 
trend to all of the neurobehavioral areas studied to be poorer in the SGA group. Namely, 
the average mean differences in scores between the study groups were 0.77 (95% CI 
0.38-1.14) for attention, 0.64 (95% CI 0.13-1.14) for habituation, 0.52 (95% CI 0.31-0.74) 
for motor, 0.95 (95% CI 0.54-1.37) for social-interactive, and 0.68 (95% CI 0.23-1.13) for 
regulation of state113. 
 
These differences persist in infants. Another study114 assessed the neurodevelopmental 
outcome at 2 years of age of children who had been SGA with cerebral blood flow 
redistribution (middle cerebral artery pulsatility index MCA PI<5th percentile). These 
children had a higher incidence of suboptimal neurodevelopmental outcome when 
compared with those with normal MCA PI (52% vs. 31%; P = 0.049)114. They also had a 
lower mean percentile in communication (53.1 vs. 67.4; P = 0.006) and problem-solving 
(39.7 vs. 47.4; P = 0.04) areas114. 
 
The differences persist later in life, being reported that all SGA groups (severe BW <-3SD; 
moderate -3<BW<-2SD; mild -2<BW<-1 SD) were associated with increased risk of poor 
school performance at time of graduation from compulsory school115. The aOR at a  
95% CI ranged from 1.85 (1.65–2.07) for severe, to 1.5 (1.43–1.58) for moderate and 1.25 
(1.22–1.28) for mild SGA115. 
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A meta-analysis116 including 28 studies on neurodevelopment of term SGA babies 
showed that SGA had a poorer performance in standardized neurodevelopment tests than 
AGA (SD 0.31; 95% CI 0.25-0.38), though there was heterogeneity among studies. 
 
 
Endocrine diseases 
 
 
Studies117, 118 suggest that SGA babies are predisposed in adulthood to metabolic 
syndrome and adult-onset diabetes (OR, 2.42; 95% CI, 1.44–4.07)118, when adjusted 
for body mass index and parental history of diabetes. 
 
A proposed model119, whereby permanent structural and functional changes in organs and 
tissues are followed by intrauterine remodeling, may help to explain the relationship 
between FGR and development of diabetes later in life. In the pancreas, a decrease in 
beta cell mass and beta cell insulin secretion is observed. In the liver, there is increased 
gluconeogenesis. In the skeletal muscle, muscle mass is decreased, with decreased 
insulin sensitivity and increased lipid oxidation. Adipose tissue has decreased insulin 
inhibition of lipolysis and decreased insulin stimulated glucose uptake. All these four 
factors, in association with increasing age and obesity, potentiate impaired glucose 
tolerance, insulin resistance and type 2 diabetes.  
 
 
 
Cardiovascular diseases  
 
Primary cardiovascular changes are already present in the SGA fetus and persist at 6 
months of age.  Both, pre and postnatally, when compared with controls, the SGA group 
showed a more globular cardiac shape, as well as signs of systolic longitudinal 
dysfunction, tricuspid annular plane systolic excursion and diastolic dysfunction. In 
addition, infants in the SGA group had increased mean blood pressure120, 121.  
 
 
1.4. SCREENING FOR SMALL FOR GESTATIONAL AGE 
 
The increased risk of perinatal mortality and morbidity of SGA can be substantially 
reduced in cases identified prenatally, as close monitoring, timely delivery and prompt 
neonatal care can be undertaken. For that, several methods of screening have been 
attempted, to optimize the outcomes. 
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1.4.1. Medical and obstetric history 
 
In the United Kingdom, where a third trimester growth scan is not offered routinely, the 
RCOG recommends that all women should be assessed at booking for risk factors for 
SGA and, based on medical history, it will be determined who requires increased 
surveillance9. 
 
The strategy of risk assessment is based on OR associated with risk factors for SGA. Risk 
factors from booking history and current pregnancy complications are taken into account 
(Tables 1.3 and 1.4). 
 
Table 1.3 RCOG risk factors for SGA fetus/neonate from history at booking9. 
Risk category Definition of risk Outcome 
(BW percentile) 
Measure Estimate 
(95% CI) 
Maternal risk factors 
Age Age ≥ 35 years < 10th population OR 1.4 (1.1–1.8) 
Age > 40 years < 10th population OR 3.2 (1.9–5.4) 
Parity Nulliparity < 10th population OR 1.9 (1.8-2.0) 
BMI BMI < 20 kg/m2 < 10th customised OR 1.2 (1.1–1.3) 
BMI 25-29.9 kg/m2 < 10th customised RR 1.2 (1.1–1.3) 
BMI ≥ 30 kg/m2 < 10th customised RR 1.5 (1.3–1.7) 
Maternal substance 
exposure 
Smoker < 10th customised AOR 1.4 (1.2–1.7) 
 1–10 cigarettes/day < 9.9th population OR 1.5 (1.4–1.7) 
≥ 11 cigarettes/day < 9.9th population OR 2.2 (2.0–2.4) 
Cocaine < 10th population OR 3.2 (2.4–4.3) 
IVF conception Singleton pregnancy < 10th percentile OR 1.6 (1.3–2.0) 
Vigorous exercise Daily < 10th customised AOR 3.3 (1.5–7.2) 
Pre pregnancy diet Low fruit intake  < 10th customised AOR 1.9 (1.3–2.8) 
Previous pregnancy history 
SGA Yes < 10th customised OR 3.9 (2.1–7.1) 
Stillbirth Yes < 10th customised OR 6.4 (0.8–52.6) 
Preeclampsia Yes < 10th population AOR 1.3 (1.2–1.4) 
Pregnancy Interval  < 6 months SGA not defined AOR 1.3 (1.2–1.3) 
 ≥ 60 months SGA not defined AOR 1.39 (1.2–1.4) 
Maternal medical history 
Maternal SGA Yes < 10th population OR 2.6 (2.3–3.1) 
Chronic hypertension Yes < 10th population ARR 2.5 (2.1–2.9) 
Diabetes Yes < 10th population OR 6 (1.5–2.3) 
Renal impairment Yes < 10th population AOR 5.3 (2.8–10) 
Antiphospholipid 
Syndrome  
Yes No definition RR 6.2 (2.43–16.0) 
Paternal medical history 
Paternal SGA Paternal SGA < 10th population OR 3.5 (1.2–10.3) 
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Table 1.4: RCOG risk factors for SGA fetus/neonate from current pregnancy 
complications9. 
Risk category Definition of risk 
Outcome 
(BW percentile) 
Measure 
Estimate 
(95% CI) 
Current pregnancy complications 
Vaginal bleeding Heavy: similar to menses < 10th population AOR 2.6 (1.2–5.6) 
Ultrasound  Echogenic bowel < 10th population AOR 2.1 (1.5–2.9) 
Preeclampsia Yes < 10th customised AOR 2.3 (1.2–4.2) 
Pregnancy induced 
hypertension 
Mild < 10th population RR 1.3 (1.3–1.4) 
Severe < 10th population RR 2.5 (2.3–2.8) 
Placental abruption Yes No definition OR - (1.3–4.1) 
Unexplained APH Yes No definition OR 5.6 (2.5–12.2) 
Low weight gain Yes < 10th population OR 4.9 (1.9–12.6) 
Exposure to caffeine ≥300 mg/day (3rd trimester < 10th population OR 1.9 (1.3–2.8) 
Serum PAPP-A < 0.4 MoM < 10th population OR 2.6 
 
 
 
Based on this factors, RCOG uses the following risk assessment strategy (Fig 1.1)9:  
 
 
Figure 1.1 - Risk assessment for SGA as set out by the RCOG9. 
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1.4.2. Clinical examination 
 
Screening for SGA by clinical examination is considered an inexpensive and effective 
method122. However, the National Institute for Health and Clinical Excellence (NICE) 2008 
guidelines on routine antenal care suggest that this can be of limited use, due to a wide 
variation in study results. 
 
 
Abdominal palpation 
 
Abdominal palpation has limited accuracy in the detection of SGA both in high and low 
risk population. In low risk population, the detection rate (DR) rounds 19-21%, whereas in 
high risk population the DR is of 37%19, 20. The results improve for severe SGA (<3rd 
percentile), with a DR of 28% in the low risk group and 53% in the high risk group19, 20. 
Regardless, RCOG advises not to perform routinely abdominal palpation as a method of 
screening9. On the other hand, in Low and/or Middle Income Countries, the World Health 
Organization (WHO) does not recommend replacing abdominal palpation with symphysis-
fundal height measurement for assessing fetal growth in order to improve perinatal 
outcomes, due to the lack of clear evidence of accuracy or superiority of either method123. 
 
 
 
Symphysis-Fundal Height Measurement 
 
Studies vary widely, with a symphysis-fundal height (SFH) measurement DR for SGA 
ranging from 27-86%124-127. The measurement is affected by fetal lie, maternal habitus, 
fibroids, amniotic fluid and fetal head engagement. Serial SFH measurements might 
improve the predictive accuracy128. Currently, RCOG9 recommends serial measurements 
of SFH, from 24 gestational weeks onwards, at each antenatal appointment. A single SFH 
below the 10th percentile or serial SFH measurements suggesting slow or static growth 
should be referred for further investigation. 
 
Plotting the measurements against customised charts might improve the prediction of 
SGA129. 
 
However, the impact of SFH measurement on perinatal outcome still remains uncertain130. 
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1.4.3. Mean arterial blood pressure 
 
Two studies reported that, as blood pressure increases between second and third 
trimester of pregnancy, BW decreases131, 132. At 28 weeks, an increase of 5mmHg (1 SD) 
in diastolic blood pressure decreases BW by 68g, whereas at 36 weeks, the same change 
reduced BW by 76g131. Also, a study showed that lower BW was only associated with a 
rise in blood pressure in the third trimester132. 
 
 
1.4.4. Ultrasound fetal biometry 
 
RCOG guidelines recommend that either EFW or AC <10th percentile can be used to 
diagnose SGA9. On the other hand, ACOG1 supports only the use of EFW<10th percentile. 
In fact, a study reports that after 24 weeks, AC and EFW < 10th percentile have similar 
ability to predict SGA133. 
 
Some studies have examined the potential value of third trimester sonographic fetal 
biometry in low-risk singleton pregnancies in the prediction of SGA neonates22-28. Three 
studies examined 725-1000 pregnancies each at 26-36 weeks’ gestation and reported 
that the EFW predicted 54-63% of SGA neonates with birth weight <10th percentile, at 
false positive rate (FPR) of 20%22-24. A study of 1868 pregnancies at 30-32 weeks 
reported that EFW predicted 73% of SGA neonates with birth weight <10th percentile, at 
FPR of 25%25. Another study of 2310 pregnancies at 30-33 weeks, reported that EFW 
predicted 60% of SGA neonates with birth weight <5th percentile, at FPR of 10%26. 
 
Up until the publication of the articles of this thesis, only one study examined the value of 
a late third trimester scan in low-risk pregnancies; the EFW in 2288 pregnancies at 34-37 
weeks’ gestation predicted 75% of SGA neonates with birth weight <5th percentile, at 
screen positive rate of 10%, which was superior to the detection rate of 58% in 3690 
pregnancies examined at 30-33 weeks27. 
 
The use of customised charts adjusted for physiological variables might improve the 
classification of fetal growth. They help identifying fetuses that are small because of 
constitutional reasons and not because of FGR, reducing unnecessary investigations and 
interventions, as well as improving the prediction of adverse outcomes8, 29. It is reported 
that the risks of stillbirth, neonatal death and Apgar score below four at five minutes were 
higher if SGA was classified by a customised, rather than by the population-based 
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birthweight standard. For stillbirth, the OR were 6.1 (95% CI 5.0-7.5) for SGA by 
customised standard only and 1.2 (95 % CI 0.8-1.9) for small for gestational age by 
population standard in comparison to infants who were AGA / LGA for both standards134. 
 
 
1.4.5. Uterine artery dopplers 
 
The uterine arteries (UtA) rise from the anterior divisions of the internal iliac arteries, 
which supply the uterus with the majority of its blood. A smaller amount of blood is 
provided from the ovarian arteries. These arteries anastomose at the level of the uterine 
cornu and originate the arcuate arteries, that run around the uterus and infiltrate into the 
outer third of the myometrium. Then, these vessels divide into the basal arteries and spiral 
arteries, which respectively supply blood  to the myometrium and intervillous space of the 
placenta. 
 
The doppler assessment of the UtA provide a non-invasive measurement of the 
resistance of the uteroplacental circulation, which is increased in FGR135. According to a 
study, UtA doppler studies provide an indication of the extent of placental pathology136.  
 
Screening for SGA, both in first137-140 and second trimesters141, have reported an increase 
in UtA PI in pregnancies that deliver SGA neonates. 
 
A review of 41131 patients from 61 studies has shown that UtA Dopplers perform more 
accurately in the second trimester rather than in the first trimester. An increased pulsatility 
index with notching was the best predictor for overall (positive likelihood ratio: LR+ 9.1) 
and severe (LR+ 14.6) FGR among low risk patients142. 
 
Second-trimester UtA resistence index (UtA RI) was associated with the risk of delivering 
an SGA infant (OR = 1.45; 95% CI: 1.27-1.65)143. A stronger association was observed in 
the third trimester, not only for UtA RI (OR = 1.66; 95% CI: 1.46- 1.89), but also for the 
presence of unilateral (OR 3.43; 95% CI, 2.36-4.97) and bilateral notching (OR 4.17; 95% 
CI, 2.54-6.82)143. 
 
Studies have shown that abnormal UtA Doppler is associated with an increased risk of 
adverse neonatal outcome, namely, delivery by CS, lower BW, low apgar scores and 
admission into Neonatal Unit144-147. Also, at diagnosis of abnormal UtA, a late SGA fetus 
has a two-fold increased risk of developing abnormal brain dopplers before induction of 
labour148.  
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1.4.5. Fetal Doppler  
 
Umbilical artery doppler 
 
The placenta is a structure of low resistance, in order to facilitate the blood exchanges. 
Hence, the fetus blood flow from the umbilical arteries (UA) to the placenta is forward. 
Once resistance in the placenta starts to increase, the resistance in the UA starts to 
increase and progressively the blood flow changes from forward during the diastole, to 
absent or even reversed. The UA PI starts to rise when 30% of the placenta is affected 
and absent or reversed end-diastolic flow translate a damage of the villous vasculature of 
at least around 60%43. 
 
A review in a high-risk population has shown that UA doppler has moderate accuracy to 
diagnose SGA (LR+ 3.76; 95% CI 2.96-4.76; LR- 0.52; 95% CI 0.45-0.61)149. 
  
Figueras et al150, studied a large population of 7645 women at 30-34 weeks. In the 369 
cases of a SGA fetus identified antenatally, those who had an abnormal UA doppler were 
more to likely to have neonatal morbidity compared to those of normal BW150. If EFW is 
below the 10th percentile, perinatal death rate can be reduced as much as 29% when the 
UA doppler is added in fetal assessment151-154.  
 
However, UA is not reliable to assess placental insufficiency in late-onset FGR. Hence, 
other doppler studies need to be examined33. 
 
 
Middle cerebral artery doppler 
 
When chronic fetal hypoxia is installed, there is redistribution of the blood flow to the brain 
and other vital organs (heart, adrenals). The brain sparing mechanism translates into 
cerebral artery vasodilation, with decreased resistance and increased velocity. Therefore, 
this clinically translates into a low middle cerebral artery (MCA) PI.  
 
There are no trials using MCA doppler to predict SGA fetuses in routine population. On 
the other hand, the studies have focused on the use of MCA to predict adverse outcomes. 
 
Focusing on late-onset FGR, studies have shown that of all term fetuses, with late-onset 
FGR and normal UA doppler, 15-20% had low MCA PI and that this was associated with 
poorer perinatal outcome and neurobehaviour145, 155. Namely, a six fold increase in risk of 
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CS for fetal distress (29% vs 4.8%; p<0.001) and a three fold increase in risk for neonatal 
acidosis (7.6 vs 2.4%; p=0.01)156. 
 
 
Cerebro-placental ratio 
 
It has been stated that combining UA and MCA in a ratio (cerebro-placental ratio - CPR), 
reflects both the placental status and fetal response, being a more sensitive doppler index 
for predicting perinatal outcome, as it is already decreased when both of its components 
are still within normal range157. In late SGA, CPR is abnormal in 20% of cases158, 159. A 
review of 9 studies regarding SGA delivered after 32 weeks, has shown that calculating 
the CPR with MCA Doppler might add value to UA Doppler assessment in the prediction 
of adverse perinatal outcome in women with a singleton pregnancy. However, this is not 
consensual and it is unclear to which subgroup of pregnant women this applies160. 
 
 
1.4.6. Biochemical markers 
 
The placenta plays a crucial role in SGA development because of multiple biological 
processes underlying fetal growth. However, valid and reliable placental biomarkers have 
not yet been determined. In late third trimester, placental growth factor and soluble fms-
like tyrosine kinase-1 are the most commonly studied biomarkers of fetal growth. 
However, findings related to these and other biomarkers are often contradictory in their 
relation to SGA. Thus, none of the biomarkers has yet been confirmed as reliable for 
predicting SGA. 
 
 
Placental growth factor 
 
Placental growth factor (PlGF) is a member of the vascular endothelial family and is 
implicated in angiogenesis and trophoblastic invasion of the maternal spiral arteries161-163. 
Some studies, mainly case-control, have reported that maternal serum PlGF is decreased 
both in the second and third trimesters164-169. Focusing in the studies170-172 that include late 
third trimester, the findings are the following (Table 1.5): 
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Table 1.5: Studies showing the differences in PlGF in normal and pregnancies delivering a SGA 
neonate.  
 
 
These studies consistently show that the levels of PlGF are lower in SGA rather than in 
their counterparts and the difference is statistically significant.  
 
 
 
Soluble fms-like tyrosine kinase-1 
 
Soluble fms-like tyrosine kinase-1 (sFlt-1) is a circulating antiangiogenic protein. It binds to 
vascular endothelial growth factor (VEGF), a protein that regulates angiogenesis, and 
PlGF. Thus, it inhibits their biological activity and has an antiangiogenic effect171, 173, 174. 
 
Focusing in the studies170-172, 174, 175 that include late third trimester, the results are mixed 
and not consistent, as stated below (Table 1.6): 
 
 
Table 1.6: Studies showing the differences in sFlt-1 in normal and pregnancies delivering a SGA 
neonate.  
Author GA 
(weeks) 
Definition of 
SGA/FGR 
Controls SGA/FGR P 
n pg/mL n pg/mL 
Wallner et al., 
2007170 
38 & 33 AC <5th and BW 
<10th  
16 2199.85 15 4479.17 0.0086 
Shibata et al., 
2005171 
39-40 BW <10th  29 2472 22 1987 0.56 
Rizos et al., 
2013172 
28-35 BW <10th  88 1616 14 1190 0.011 
Chaiworapongsa 
et al., 2008174 
20-40 EFW  <10th  135 1445 53 3603 <0.001 
Romero et al., 
2008175 
40 BW <10th  46 - 56 - 0.8285 
 
 
Both Wallner et al170  and Chaiworapongsa et al174 have shown that sFlt-1 is significantly 
higher in pregnancies delivering SGA. Also, by breaking down the results by Doppler 
findings, it was seen that the concentration of sFlt-1 was highest in SGA fetuses with 
abnormal UtA Doppler or abnormal UA and UtA dopplers. 
Author GA 
(weeks) 
Definition of 
SGA/FGR 
Controls SGA/FGR P 
n pg/mL N pg/mL 
Wallner et 
al., 2007170 
38 & 33 AC <5th and BW 
<10th 
16 245.74 15 48.4 0.0017 
Shibata et 
al., 2005171 
39-40 BW <10th 31 266 24 163 <0.0001 
Rizos et al., 
2013172 
28-35 BW <10th 88 780 14 512 0.002 
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sFlt-1/PlGF ratio 
 
As studies show a decrease in PlGF and an increase in sFlt-1 in SGA fetuses164-169, there 
is a potential to use the ratio sFlt-1/PlGF to improve the detection of SGA. The data 
refering to late SGA, without PE is scarce and not significant, as shown in the table below. 
 
Table 1.7: Difference in PlGF/sFlt-1 ratio in normal and pregnancies delivering a SGA neonate. 
 
Author GA 
(weeks) 
Definition SGA/FGR Controls SGA/FGR P 
n sFlt-1/PIGF  n sFlt-1/PIGF  
Herraiz et 
al., 2014169 
>34 EFW <10th percentile + 
AFI <10th percentile or UA 
PI>95th percentile 
171 11.0 8 116.8 <0.5 
 
 
 
1.4.7. Combination models 
 
Combination models for SGA fetuses without pre-eclampsia have focused mainly in the 
first, second and early third trimester. 
 
For first trimester, the algorithms combining maternal characteristics, biophysical and 
biochemical tests have shown an improvement in the early detection of SGA. A screening 
study at 11-13 weeks established an algorithm for the prediction of SGA in absence of PE 
based on maternal characteristics, biochemical (PAPP-A, free ß-hCG, PlGF, PP13, 
ADAM12) and biophysical markers (UtA PI, MAP and Nuchal translucency). It concluded 
that half the pregnancies with SGA neonates, in the absence of PE, could be identified at 
11-13 weeks137.  
 
Models developed for the second trimester also showed an improvement in the detection 
SGA without PE. A study using maternal characteristics, EFW and UtA PI on the second 
trimester was predictive for SGA (R2 0.225, AUC 0.815). It also demonstrated that the 
additional use of a third trimester scan (EFW, UtA PI, UA PI) and maternal characteristics, 
improved the prediction of SGA (combined model: R2 0.423, AUC 0.896)176. 
 
For early third trimester, a study comparing the detection rate for SGA between EFW and 
EFW combined with uterine artery doppler showed that adding Doppler velocimetry to 30-
32 weeks EFW improves the specificity (84%) regarding SGA newborns, maintaining a 
good detection rate (71%). Thus reducing the population needed to be rescreened from 
27 to 17% according to the study model25.  
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There is very limited data screening for SGA in late third trimester with combination 
models. Regarding late-onset FGR, Crispi et al, developed a combination model of 
UtA Doppler with PlGF, for identifying late-onset PE/IUGR. However, besides not 
discriminating SGA with and without PE, it did not perform well, with a detection rate 
below 11% for all parameters analyzed, for a specificity of 95% (UtA PI and sFlt1 - DR 
5.3; PlGF and sFlt1 - DR 5.3; UtA PI and sFlt1/PlGF ratio - DR 10.5)167. 
 
Despite lack of models for late SGA screening, there is more data involving prediction of 
adverse outcomes. Namely, a model combining SGA (EFW<3rd percentile) with Doppler 
studies (CPR <10th percentile and UtA>95th percentile) increased the risk of predicting 
adverse neonatal outcomes. The algorithm had a detection rate of 82.8% (95% CI, 75.1-
88.6%) for prediction of adverse outcomes177. 
 
 
 
1.5. OBJECTIVES OF THE THESIS 
 
Up until the publication of the articles of this thesis, only one study examined the value of 
a late third trimester scan in low-risk pregnancies to predict SGA neonates. Furthermore, 
there is not a single trial that combined all the above described methods to predict SGA 
late in pregnancy.  
 
Hence, the objective of this thesis is to assess the combination of maternal factors and 
biophysical and biochemical markers at 35-37 gestational weeks to predict SGA neonates 
in the absence of preeclampsia. 
 
This will facilitate targeted surveillance and early intervention. In order to develop a 
clinically useful screening test, algorithms should be derived from multivariable logistic 
regression analysis combining maternal characteristics, biophysical and biochemical 
markers. Therefore, a new approach to antenatal care can be proposed, whereby the 
patient-specific risk for a wide variety of pregnancy complications is estimated at 35-37 
weeks, at the same time we perform the routine growth scan. This will be followed by an 
individualized patient and disease specific approach, both in terms of the schedule and 
content of subsequent antenatal care. 
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CHAPTER 2 
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Chapter 2. Patients and Methods 
 
 
2.1 STUDY POPULATION 
 
This is a prospective screening study for detection of SGA, in women attending for their 
routine third-trimester hospital visit in pregnancy at King’s College Hospital (London) and 
Medway Maritime Hospital (Kent), between February and December 2014. This visit, at 
35-37 gestational weeks (gestational age being determined by the measurement of fetal 
crown-rump length at 11-13 weeks or fetal head circumference after that), includes: 
 
 - Recording of information regarding maternal characteristics and medical history; 
- Assessment of blood pressure and mean arterial blood pressure (MAP) by automated 
devices; 
- Ultrasound examination for estimation of fetal weight178 from transabdominal 
measurement of fetal biparietal diameter (BPD), head circumference (HC), abdominal 
circumference and femur length (FL)179, as well as mesurement of UtA PI; 
- Measurement of maternal serum metabolites PlFG and sFlt-1. 
 
The entry criteria for the study are singleton pregnancies that resulted in live birth or 
stillbirth of phenotypically normal babies. 
 
 
 
2.2. ETHICAL COMITTEE APPROVAL 
 
Written informed consent was obtained from the women agreeing to participate in a study 
on adverse pregnancy outcome, which was approved by the Ethics Committee of each 
participating hospital. 
 
 
 
2.3. DATA COLLECTION 
 
2.3.1. Maternal characteristics and history 
 
The following information was recorded from a medical interview: 
• Maternal age 
• Racial origin (Caucasian, Afro-Caribbean, South Asian, East Asian and mixed) 
  51 
• Method of conception (spontaneous or assisted conception requiring the use of 
ovulation drugs or in vitro fertilisation (IVF)) 
• Cigarette smoking during pregnancy (yes or no) 
• History of chronic hypertension (yes or no) 
• History of type 1 or 2 diabetes mellitus (yes or no) 
• History of systemic lupus erythematosus (SLE) or antiphospholipid syndrome 
(APLS) (yes or no) 
• Family history of PE in the mother of the patient (yes or no)  
• Obstetric history: 
✓ Parity (parous or nulliparous, if no previous pregnancies at or after 24 
weeks) 
✓ Previous pregnancy with PE (yes or no) 
✓ Previous pregnancy with SGA babies (yes or no)  
✓ Inter-pregnancy interval.  
Maternal weight and height were also recorded. 
 
 
2.3.2. Mean arterial blood pressure 
 
Blood pressure (BP) was taken by automated devices (3BTO-A2, Microlife, Taipei, 
Taiwan), which were calibrated before and at regular intervals during the study. Doctors 
who have received appropriate training on the use of these machines made the record. 
The women were in sitting position, with their arms supported at the level of the heart and 
either a small (<22 cm), normal (22-32 cm) or large (33-42 cm) adult cuffs were used 
depending on the mid-arm circumference. After rest for five minutes, two recordings of 
MAP were made in both arms simultaneously. Final MAP was calculated as the average 
of all four measurements. 
 
2.3.3. Estimated fetal weight 
 
Ultrasound was performed by operators trained by the Fetal Medicine Foundation and 
who had a Certificate of Competence both for anomaly scan and fetal doppler 
assessment. 
 
The images recquired for assessing fetal biometry were: 
- BPD and HC: Transverse view of the head at the level of the septum pellucidum cavum 
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- AC: Transverse view of the abdomen at the level of the umbilical vein and stomach 
- FL: Longitundinal view of the femur 
 
EFW was calculated using Hadlock's formula178: 
 
 
 
2.3.4. Measurement of uterine artery doppler 
 
Transabdominal colour Doppler ultrasound is used to visualize the left and right uterine 
arteries at the apparent crossover with the external iliac arteries. Pulsed-wave Doppler is 
then used with the sampling gate set at 2 mm to cover the whole vessel. Care is taken to 
ensure that the angle of insonation is less than 30º and the peak systolic velocity is 
greater than 60 cm/s to ensure that the uterine artery, rather than the arcuate artery, is 
examined. When three similar consecutive waveforms are obtained the PI is measured 
and the mean PI of the left and right arteries calculated.  
 
 
 
2.3.5. Biochemical measurements 
 
Maternal venous blood is processed within 15 minutes of blood sampling. Serum PlGF 
and sFlt-1 are measured in parallel, using an automated electrochemiluminescence 
immunoassay system (Cobas e411, Roche Diagnostics, Penzberg, Germany).  
 
The interassay coefficients of variation for the low and high concentrations were 5.4% and 
3.0% for PlGF and 3.0% and 3.2% for sFlt-1, respectively. The Cobas e411 covers a 
measurement range from 3 to 10 000 pg/mL for PlGF and from 10 to 85 000 pg/mL for  
sFlt-1.  
 
 
2.3.6. Outcome measures 
 
Data on pregnancy outcome was collected from the hospital maternity records or the 
general medical practitioners of the women. 
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The primary outcome of the study was SGA without PE. The newborn was considered to 
be SGA if the birth weight was less than the 5th percentile after correction for gestational 
age at delivery (SGA<5th)180. The definitions of non-proteinuric gestational hypertension 
(GH) and PE were those of the International Society for the Study of Hypertension in 
Pregnancy181. The obstetric records of all women with pre-existing or pregnancy 
associated hypertension were examined to confirm if the condition was chronic 
hypertension, PE or GH. The patients who developed pre-eclampsia were excluded. 
 
 
2.4. STATISTICAL ANALYSIS  
 
The observed measurements of fetal HC, AC, FL and EFW were expressed as the 
respective Z-score and percentile, corrected for gestational age179, 182. Mann Whitney-U 
test was used to compare the Z-score and percentile values of HC, AC, FL and EFW 
between the SGA and unaffected groups. Regression analysis was used to determine the 
significance of association between HC Z-score, AC Z-score, FL Z-score and EFW Z-
score with the time interval between assessment and delivery.  
 
The values of uterine artery PI, MAP, PlGF and sFlt-1 were log10 transformed to make 
their distributions Gaussian. Each measured value in the outcome groups was expressed 
as a multiple of the normal median (MoM) after adjustment for those characteristics found 
to provide a substantial contribution to the log10 transformed value183-186. Mann Whitney-U 
test was used to compare the median MoM values of uterine artery PI and MAP between 
the outcome groups. Regression analysis was used to determine the significance of 
association between log10 MoM of uterine artery PI, MAP, PlGF and sFlt-1 with 
assessment to delivery interval and birth weight Z-score.  
 
The a priori risk for SGA<5th were calculated using multivariable logistic regression 
analysis with backward stepwise elimination to determine which of the factors among 
maternal characteristics and obstetric history had a significant contribution in predicting 
SGA<5th.  
 
Multivariable logistic regression analysis was used to determine if the maternal factor-
derived logit (a priori risk), Z-score of biometries (HC, AC, FL or EFW) or log10MoM value 
of the remaining biophysical and biochemical markers (MAP, UtA PI, PlGF and sFlt-1) had 
significant contribution in predicting SGA<5th. The performance of screening was 
determined by receiver operating characteristic (ROC) curves. Similarly, the algorithm was 
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used to determine the performance of screening for SGA defined by birth weight  
<10th percentile (SGA<10th) and SGA with birth weight <3rd percentile (SGA<3rd) delivering 
<2 weeks following assessment and delivering ≥37 weeks' gestation. 
 
 
The statistical software package SPSS 22.0 (SPSS Inc.,Chicago, IL) and Medcalc 
(Medcalc Software, Mariakerke, Belgium) were used for all data analyses. 
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Chapter 3: Screening by maternal charateristics and fetal biometry at 35-37 weeks 
 
 
ABSTRACT 
 
Objective: To investigate the value of fetal biometry at 35-37 weeks’ gestation in the 
prediction of delivery of small for gestational age (SGA) neonates, in the absence of 
preeclampsia (PE). 
 
Methods: Screening study in singleton pregnancies at 35-37 weeks, including 278 that 
delivered SGA neonates with birth weight <5th percentile and 5237 cases unaffected by 
SGA, PE or gestational hypertension. Multivariable logistic regression analysis was used 
to determine if screening by a combination of maternal factors and Z-scores of fetal head 
circumference (HC), abdominal circumference (AC) and femur length (FL) or estimated 
fetal weight (EFW) had a significant contribution in predicting SGA neonates.  
 
Results: Combined screening by maternal characteristics and history with EFW Z-scores 
at 35-37 weeks, predicted 89% of SGA neonates with birth weight <5th percentile 
delivering<2 weeks following assessment, at 10% false positive rate (FPR). The detection 
rate for the prediction of SGA neonates delivering after 37 weeks was 70%. The 
performance of screening by a combination of Z-scores for fetal HC, AC and FL was 
similar to that achieved by the EFW Z-score. 
 
Conclusion: Combined testing by maternal characteristics and fetal biometry at 35-37 
weeks could identify, at a 10% FPR, 90% of pregancies that subsequently deliver SGA 
neonates within 2 weeks of assessment and 70% of those that deliver after 37 weeks. 
 
This chapter is based on: Fadigas C, Saiid Y, Gonzalez R, Poon LC and Nicolaides KH. 
Prediction of small-for-gestational age neonates: screening by fetal biometry at 35-37 
weeks. Ultrasound Obstet and Gynecol. 2015; 45: 559-65. 
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3.1. INTRODUCTION 
 
Small for gestational age (SGA) neonates are at increased risk of perinatal mortality and 
morbidity, but the risks can be substantially reduced if the condition is identified prenatally, 
because in such cases close monitoring and appropriate timing of delivery and prompt 
neonatal care can be undertaken110. 
 
A few studies have examined the potential value of sonographic fetal biometry in low-risk 
singleton pregnancies during the third trimester in the prediction of SGA neonates22-28. 
The studies report that the estimated fetal weight (EFW) at 26-36 gestational weeks 
predicted 54-63% of SGA neonates with BW <10th percentile, at false positive rate (FPR) 
of 20%22-24 and 73% of SGA at FPR of 25% with an ultrasound at 30-32 weeks25. For SGA 
defined with neonate with BW<5th percentile, it was reported that EFW at 30-33 weeks 
had a DR of 60%, at FPR of 10%26. Only one study examined the value of a late third 
trimester scan in low-risk pregnancies. For that, the EFW 34-37 weeks’ gestation, in 2288 
pregnancies, predicted 75% of SGA neonates with BW <5th percentile, at a FPR of 10%, 
which was superior to the detection rate of 58%, in 3690 pregnancies examined at 30-33 
weeks27.  
 
Since completion of this thesis studies, colleagues from the same department reported the 
findings from a screening study at 30-34 weeks in 30849 singleton pregnancies28. 
Combined screening by maternal characteristics and history with EFW Z-scores, predicted 
79%, 87% and 92% of SGA neonates in the absence of PE delivering at <5 weeks 
following assessment with birth weights <10th, <5th and <3rd percentiles, respectively, at a 
10% FPR. The respective detection rates for prediction of SGA neonates delivering at >5 
weeks following assessment were 53%, 58% and 61%. Consequently, the performance of 
screening for SGA at 30-34 weeks is acceptably high for those delivering preterm, but 
disappointingly low for those delivering at term. 
 
 
3.1.1. Objectives 
 
The objectives of this study in a large cohort of singleton pregnancies undergoing routine 
antenatal care are firstly, to investigate further the potential value of fetal biometry at  
35-37 weeks’ gestation in the prediction of delivery of SGA neonates in the absence of PE 
and secondly, combine these biomarkers with maternal characteristics and history to 
develop specific algorithms for the calculation of patient-specific risks for SGA. 
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3.2. METHODS 
 
The data for this study was derived from prospective screening for adverse obstetric 
outcomes in women attending for their routine hospital visit in the third trimester of 
pregnancy at 35+0-37+6 weeks’ gestation. The methodology for recording of patient 
characteristics, sonographic estimation of EFW, mean arterial blood pressure (MAP), UtA 
PI, maternal serum metabolites, outcome measures and statistical analysis was as 
described in Chapter 2.  
 
 
 
3.3. RESULTS 
 
The study population comprised of 5515 pregnancies, including 278 (5.0%) that delivered 
SGA<5th neonates in the absence of PE and 5237 (95.0%) cases that were unaffected by 
these outcomes. The characteristics of the study population are given in Table 3.1.  
 
 
Table 3.1 Characteristics of the study population of women with a singleton pregnancy with normal outcome 
or with a small-for-gestational-age (SGA) neonate, in the absence of pre-eclampsia (PE). 
SLE = systemic lupus erythematosus; APLS = antiphospholipid syndrome; IQR = interquartile range; PE = preeclampsia; 
SGA = small for gestational age 
 
Characteristic Normal 
(n=5237) 
SGA without PE 
(n=278) 
P-value 
Maternal age in years, median (IQR) 31.2 (26.5-35.0) 30.1 (24.8-35.3) 0.067 
Maternal weight in Kg, median (IQR) 79.0 (70.9-89.9) 73.2 (64.2-83.5) <0.0001 
Maternal height in cm, median (IQR) 164 (160-168) 162 (157-165) <0.0001 
Gestation at screening in weeks, median (IQR) 36.1 (36.0-36.4) 36.3 (36.0-36.4) 0.916 
Racial origin    
   Caucasian, n (%) 3720 (71.0) 161 (57.9) <0.0001 
   Afro-Caribbean, n (%) 1034 (19.7) 64 (23.0) 0.190 
   South Asian, n (%) 199 (3.8) 34 (12.2) <0.0001 
   East Asian, n (%) 109 (2.1) 6 (2.2) 0.830 
   Mixed, n (%) 175 (3.3) 13 (4.7) 0.233 
Past obstetric history    
   Nulliparous, n (%) 2537 (48.4) 172 (61.9) 0.001 
   Parous with no prior PE and SGA, n (%) 2481 (47.4) 73 (26.3) <0.0001 
   Parous with prior PE no SGA, n (%) 82 (1.6) 5 (1.8) 0.459 
   Parous with prior SGA no PE, n (%) 127 (2.4) 27 (9.7) 0.002 
   Parous with prior SGA and PE, n (%) 10 (0.2) 1 (0.4) >0.999 
Inter-pregnancy interval in years, median (IQR) 3.1 (2.1-5.1) 2.9 (2.1-5.5) 0.965 
Cigarette smoker, n (%) 503 (9.6) 62 (22.3) <0.0001 
Conception    
   Spontaneous, n (%) 5110 (97.6) 266 (95.7) 0.072 
   Ovulation drugs, n (%) 23 (0.4) 2 (0.7) 0.362 
   In vitro fertilization, n (%) 104 (2.0) 10 (3.6) 0.079 
Chronic hypertension 72 (1.4) 2 (0.7) 0.588 
Pre-existing diabetes mellitus, n (%) 65 (1.2) 3 (1.1) >0.999 
   Type 1, n (%) 31 (0.6) 2 (0.7) >0.999 
   Type 2, n (%) 34 (0.6) 1 (0.4) >0.999 
SLE / APS, n (%) 13 (0.2) 0 (0.0) >0.999 
Gestation at delivery in weeks, median (IQR) 40.0 (39.0-40.9) 39.4 (38.4-40.4) <0.0001 
Birth weight in grams, median (IQR) 3430 (3140-3745) 2550 (2347-2721) <0.0001 
Birth weight in percentile, median (IQR) 50.3 (26.6-75.6) 2.7 (1.2-3.7) <0.0001 
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In the SGA group, compared with the normal group, there was a lower median maternal 
weight and height, a higher prevalence of South Asian racial origin, nulliparous women, 
parous women with a prior history of SGA and cigarette smokers, and a lower prevalence 
of Caucasian racial origin and parous women without prior history of SGA and PE. The 
median gestational age at delivery and neonatal birth weight were significantly lower in the 
SGA group than in the normal group.   
 
There were significant (p<0.0001) intercorrelations between Z-score values of HC, AC, FL 
and EFW in both SGA and normal outcome groups (Table 3.2). 
 
 
Table 3.2 Pearson correlation between Z-score values of head circumference, abdominal circumference, 
femur length and estimated fetal weights at 35-37 weeks’ gestation in the normal and small for gestational age 
groups. 
 
Z-score values 
Head 
circumference 
Abdominal 
circumference 
Femur length Estimated fetal 
weight 
Normal SGA Normal SGA Normal SGA Normal SGA 
Head 
circumference 
r 1 1 0.373 0.381 0.146 0.234 0.592 0.545 
p - - <0.0001 <0.0001 <0.0001 0.001 <0.0001 <0.0001 
Abdominal 
circumference 
r 0.373 0.381 1 1 0.238 0.254 0.916 0.867 
p <0.0001 <0.0001 - - <0.0001 <0.0001 <0.0001 <0.0001 
Femur length 
r 0.146 0.234 0.238 0.254 1 1 0.469 0.622 
p <0.0001 0.001 <0.0001 <0.0001 - - <0.0001 <0.0001 
Estimated 
fetal weight 
r 0.592 0.545 0.916 0.867 0.469 0.622 1 1 
p <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 - - 
   r  = Pearson correlation, SGA = small for gestational age 
 
 
3.3.1. Normal pregnancy outcome 
 
There was a significant linear association between HC Z-score and the assessment to 
delivery interval (-0.298 + 0.040 x delivery interval; r=0.087; P<0.0001) and between EFW 
Z-score with assessment-to-delivery interval (0.281 + 0.025 x delivery interval; r=0.047; 
P=0.001) and there was a significant polynomial association between AC Z-score with 
assessment-to-delivery interval (-0.146 + 0.077 x delivery interval – 0.010 x delivery 
interval 2; r=0.040; P=0.015) and between FL Z-score with assessment-to-delivery interval 
(-0.215 + 0.194 x delivery interval – 0.053 x delivery interval 2 + 0.005 x delivery interval 3; 
r=0.043; P=0.022).  
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3.3.2. Small for gestational age  
 
In the SGA<5th group, the median Z-score values of HC, AC, FL and EFW at 35-37 weeks 
were significantly lower (p<0.0001). There was a significant linear association between 
HC Z-score with assessment-to-delivery interval (-1.147 + 0.098 x delivery interval; 
r=0.249; P<0.001 (Figure 3.1.a); AC Z-score with assessment-to-delivery interval (-1.684 
+ 0.214 x delivery interval; r=0.481; P<0.0001; Figure 3.1.b); FL Z-score with assessment-
to-delivery interval (-1.263 + 0.190 x delivery interval; r=0.314; P<0.0001; Figure 3.1.c); 
and EFW Z-score with assessment-to-delivery interval (-1.572 + 0.234 x delivery interval; 
r=0.505; P<0.0001; Figure 3.1.d). 
 
 
 
 
Figure 3.1 Z-scores for fetal head circumference (A), abdominal circumference (B), femur length 
(C) and estimated fetal weight (D) at 35-37 weeks 
 
 
 
 
The a priori risk for SGA<5th is calculated from the following formula: odds/(1+odds), 
where odds=eY and Y is derived from multivariable logistic regression analysis. 
Regression coefficients and adjusted odds ratios of each of the maternal factors in the 
prediction algorithms are presented in Table 3.3 (R2=0.106, p<0.0001). 
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Table 3.3 Fitted regression model with maternal characteristics and history for the prediction of 
small for gestational age with birth weight below the 5th percentile in the absence of preeclampsia. 
 
Subtracted from maternal weight in kg†. Subtracted from maternal height in cm§. SE, standard error. 
 
 
The likelihood of SGA<5th decreased with maternal weight and height, and in parous 
women the risk increased with inter-pregnancy interval. The risk was higher in women of 
Afro-Caribbean and South Asian racial origin, in cigarette smokers, in nulliparous women, 
and in those with prior history of SGA, with or without prior PE. The risk was lower in 
parous women without prior history of SGA, with or without prior PE. The likelihood of 
SGA<5th was not significantly altered by maternal age (p=0.911), method of conception 
(p=0.083), chronic hypertension (p=0.502), diabetes mellitus (p=0.645) and SLE or APS 
(P=0.998). 
 
Multivariable logistic regression analyses demonstrated that, in the prediction of SGA<5th, 
there were significant contributions from maternal characteristics and a combination of HC 
Z-score, AC Z-score and FL Z-score or EFW Z-score (Table 3.4).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Independent variable Coefficient SE OR 
(95% CI) 
P-value 
Intercept -0.89206 0.39700 - - 
Weight (-75)† -0.02012 0.01094 0.980 (0.970-0.990) <0.0001 
Height (- 165)§ -0.03839 0.01094 0.962 (0.942-0.983) 0.0004 
Racial origin     
   Caucasian, East Asian, mixed (reference) 0  1  
   Afro-Caribbean 0.56782 0.15750 1.764 (1.296-2.403) 0.0003 
   South Asian 1.08597 0.21540 2.962 (1.942-4.518) <0.0001 
Cigarette smoking 1.08264 0.16094 2.952 (2.154-4.047) <0.0001 
Past obstetric history and pregnancy interval     
   Nulliparous 1.06018 0.16341 2.887 (2.096-3.977) <0.0001 
   Parous     
      No previous SGA, with or without PE (reference) -3.23409 0.17404 0.021  
      Interpregnancy interval in years 0.06583 0.02655 1.081 (1.026-1.139) 0.003 
      Previous SGA, with or without PE 1.59429 0.23809 6.639 (4.163-10.587) <0.0001 
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Table 3.4 Fitted regression models with maternal characteristics and history, fetal head circumference (HC) Z-
score, abdominal circumference (AC) Z-score, femur length (FL) Z-score or estimated fetal weight (EFW) Z-
score at 35–37 weeks’ gestation, for the prediction of small-for-gestational age with birth weight < 5th 
percentile in the absence of pre-eclampsia 
 
OR, odds ratio; SE, standard error. 
 
 
 
The areas under the ROC curves (AUC) and the DRs at a false-positive rate (FPR) of 5% 
and 10% and FPRs for DRs of 100%, 90% and 80% of SGA<10th, SGA<5th and SGA<3rd 
delivering <2 weeks after assessment and ≥ 37 weeks' gestation, when screening by 
maternal characteristics and a combination of HC, AC and FL Z-scores or EFW Z-scores 
are given in Table 3.5, 3.6 and 3.7 in and Figure 3.2. 
Independent variable Coefficient SE OR 95% CI P 
HC Z-score, AC Z-score, FL Z-score (R2 = 0.385, P < 0.0001) 
Intercept -4.63644 0.17774 - - - 
HC Z-score -1.69241 0.38801 0.184 0.086-0.394 <0.0001 
HC Z-score2 -1.38647 0.58648 0.250 0.079-0.789 0.018 
HC Z-score3 -0.57469 0.24992 0.563 0.345-0.919 0.021 
AC Z-score -2.70720 0.31467 0.067 0.036-0.124 <0.0001 
AC Z-score2 -0.42986 0.15646 0.651 0.479-0.884 0.006 
FL Z-score -0.58584 0.10142 0.557 0.456-0.679 <0.0001 
EFW Z-score (R2 = 0.382, P < 0.0001) 
Intercept -3.54921 0.10191 - - - 
EFW Z-score -2.69024 0.12566 0.068 0.053-0.087 <0.0001 
Maternal characteristics and history with HC Z-score, AC Z-score and FL Z-score (R2=0.404, P < 0.0001) 
Intercept -2.96574 0.30796 - - - 
Logit (a-priori risk) 1.23133 0.19699 3.426 2.329-5.040 <0.0001 
HC Z-score -1.58736 0.39123 0.204 0.095-0.440 <0.0001 
HC Z-score2 -1.43277 0.59159 0.239 0.075-0.761 0.015 
HC Z-score3 -0.60812 0.25210 0.544 0.332-0.892 0.016 
AC Z-score -2.59686 0.31677 0.075 0.040-0.139 <0.0001 
AC Z-score2 -0.41541 0.15819 0.660 0.484-0.900 0.009 
FL Z-score -0.55642 0.10197 0.573 0.469-0.700 <0.0001 
Maternal characteristics and history with EFW Z-score (R2=0.402, P < 0.0001) 
Intercept -1.93604 0.25984 - - - 
Logit (a-priori risk) 1.25042 0.19651 3.492 2.376-5.132 <0.0001 
EFW Z-score -2.54708 0.12867 0.078 0.061-0.101 <0.0001 
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Table 3.5 Performance of screening for small for gestational age (SGA) neonates with birthweight <10th, <5th and <3rd percentiles, delivering within 2 weeks 
of assessment and ≥ 37 weeks' gestation, in the absence of pre-eclampsia, using maternal characteristics and history, fetal biometry or estimated fetal weight 
at 35-37 weeks' gestation 
 
Screening test AUC 
Detection rate (%) FPR (%) 
FPR 5% FPR 10% DR 100% DR 90% DR 80% 
SGA delivering <2 weeks following assessment      
Small for gestational age <10th percentile       
        Maternal characteristics and history 0.735 (0.722-0.747) 26.5 (18.1-36.4) 41.8 (31.9-52.2) 98.4 (98.0-98.7) 71.0 (69.7-72.3) 52.1 (50.7-53.5) 
        Plus EFW z-score 0.961 (0.955-0.966) 77.6 (68.0-85.4) 87.8 (79.6-93.5) 53.5 (52.1-54.9) 11.9 (11.0- 12.8) 5.8 (5.1-6.5) 
Small for gestational age <5th percentile       
        Maternal characteristics and history 0.804 (0.793-0.815) 35.9 (23.1-50.2) 50.0 (36.6-64.9) 73.6 (72.4-74.8) 57.9 (56.6-59.3) 44.8 (43.5-46.2) 
        Plus EFW z-score 0.972 (0.967-0.976) 84.9 (72.4-93.3) 88.7 (77.0-95.7) 34.6 (33.3-35.9) 11.1 (10.2-12.0) 3.0 (2.5-3.5) 
Small for gestational age <3rd percentile       
        Maternal characteristics and history 0.807 (0.796-0.818) 38.9 (23.1-56.5) 50.0 (32.9-67.1) 62.4 (61.1-63.7) 57.9 (56.6-59.3) 40.5 (39.1-41.8) 
        Plus EFW z-score 0.983 (0.979-0.986) 91.7 (77.5-98.2) 91.7 (77.5-98.2) 17.1 (16.1-18.2) 3.8 (3.3-4.3) 0.9 (0.7-1.3) 
SGA delivering ≥37 weeks' gestation       
Small for gestational age <10th percentile       
        Maternal characteristics and history 0.709 (0.697-0.721) 19.7 (16.6-23.1) 32.2 (28.5-36.1) 99.9 (99.8-99.9) 70.5 (69.2-71.7) 53.4 (52.0-54.8) 
        Plus EFW z-score 0.887 (0.879-0.895) 46.9 (42.9-51.0) 66.0 (62.0-69.7) 88.5 (87.6-89.4) 32.9 (31.6-34.2) 19.5 (18.4-20.6) 
Small for gestational age <5th percentile       
        Maternal characteristics and history 0.734 (0.722-0.746) 22.4 (17.5-28.0) 35.7 (29.9-41.9) 98.1 (97.7-98.5) 68.8 (67.5-70.0) 49.7 (48.3-51.0) 
        Plus EFW z-score 0.906 (0.898-0.913) 53.6 (47.4-59.8) 70.0 (64.0-75.4) 83.4 (82.4-84.4) 25.0 (23.9-26.2) 13.5 (12.6-14.5) 
Small for gestational age <3rd percentile       
        Maternal characteristics and history 0.772 (0.761-0.784) 24.8 (18.1-32.6) 37.6 (29.8-45.9) 90.7 (89.9-91.5) 56.3 (54.9-57.6) 41.7 (40.4-43.1) 
        Plus EFW z-score 0.928 (0.921-0.935) 63.8 (55.5-71.5) 77.2 (69.6-83.7) 69.3 (68.0-70.5) 19.6 (18.5-20.7) 10.6 (9.8-11.5) 
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Table 3.6 Detection rates (DR) in screening for small-for-gestational-age neonates with birth weight < 10th, < 5th and < 3rd percentile, delivering within 2 weeks 
of assessment, in the absence of pre-eclampsia, using maternal characteristics and history, fetal biometry or estimated fetal weight at 35–37 weeks’ gestation 
 
 
 
 
 
 
 
 
Screening test AUC 
DR (%) FPR (%) 
FPR = 5% FPR = 10% DR = 100% DR = 90% DR = 80% 
Small for gestational age <10th percentile       
Maternal characteristics and history  0.735 (0.722–0.747) 26.5 (18.1–36.4) 41.8 (31.9–52.2) 98.4 (98.0–98.7) 71.0 (69.7–72.3) 52.1 (50.7–53.5) 
HC Z-score, AC Z-score, FL Z-score 0.954 (0.948–0.959) 77.6 (68.0–85.4) 82.7 (73.7–89.6) 48.1 (46.7–49.5) 16.4 (15.4–17.4) 5.8 (5.2–6.5) 
EFW Z-score 0.959 (0.953–0.964) 79.6 (70.3–87.1) 86.7 (78.4–92.7) 59.5 (58.1–60.9) 13.8 (12.9–14.8) 5.4 (4.9–6.2) 
Maternal characteristics and history plus       
       HC Z-score, AC Z-score, FL Z-score 0.957 (0.952–0.963) 77.6 (68.0–85.4) 85.7 (77.2–92.0) 43.6 (42.2–45.0) 13.3 (12.3–14.3) 6.7 (6.0–7.4) 
       EFW Z-score 0.961 (0.955–0.966) 77.6 (68.0–85.4) 87.8 (79.6–93.5) 53.5 (52.1–54.9) 11.9 (11.0–12.8) 5.8 (5.1–6.5) 
Small for gestational age <5th percentile       
Maternal characteristics and history  0.804 (0.793–0.815) 35.9 (23.1–50.2) 50.9 (36.8–64.9) 73.6 (72.4–74.8) 57.9 (56.6–59.3) 44.8 (43.5–46.2) 
HC Z-score, AC Z-score, FL Z-score 0.960 (0.954–0.965) 81.1 (68.0–90.6) 86.8 (74.7–94.5) 45.4 (44.1–46.8) 13.8 (12.9–14.8) 4.8 (4.3–5.4) 
EFW Z-score 0.964 (0.959–0.969) 83.0 (70.2–91.9) 86.8 (74.7–94.5) 43.4 (42.0–44.7) 13.1 (12.2–14.0) 3.7 (3.2–4.3) 
Maternal characteristics and history plus       
       HC Z-score, AC Z-score, FL Z-score 0.969 (0.964–0.973) 81.1 (68.0–90.6) 90.6 (79.3–96.9) 38.1 (36.8–39.4) 10.0 (9.2–10.8) 3.9 (3.4–4.4) 
       EFW Z-score 0.972 (0.967–0.976) 84.9 (72.4–93.3) 88.7 (77.0–95.7) 34.6 (33.3–35.9) 11.1 (10.2–12.0) 3.0 (2.5–3.5) 
Small for gestational age <3rd percentile       
Maternal characteristics and history  0.807 (0.796–0.818) 38.9 (23.1–56.5) 50.0 (32.9–67.1) 62.4 (61.1–63.7) 57.9 (56.6–59.3) 40.5 (39.1–41.8) 
HC Z-score, AC Z-score, FL Z-score 0.973 (0.969–0.978) 86.1 (70.5–95.3) 88.9 (73.9–96.9) 20.0 (18.9–21.1) 13.7 (12.7–14.6) 1.6 (1.2–1.9) 
EFW Z-score 0.980 (0.976–0.984) 88.9 (73.9–96.9) 91.7 (77.5–98.2) 18.6 (17.5–19.7) 8.4 (7.6–9.2) 1.7 (1.3–2.1) 
Maternal characteristics and history plus       
       HC Z-score, AC Z-score, FL Z-score 0.979 (0.975–0.983) 83.3 (67.2–93.6) 91.7 (77.5–98.2) 17.4 (16.4–18.4) 9.1 (8.4–10.0) 1.1 (0.8–1.4) 
       EFW Z-score 0.983 (0.979–0.986) 91.7 (77.5–98.2) 91.7 (77.5–98.2) 17.1 (16.1–18.2) 3.8 (3.3–4.3) 0.9 (0.7–1.3) 
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Table 3.7 Detection rates (DR) in screening for small-for-gestational-age neonates with birth weight < 10th, < 5th and < 3rd percentile, delivering ≥ 37 weeks’ 
gestation, in the absence of pre-eclampsia, using maternal characteristics and history, fetal biometry or estimated fetal weight at 35–37 weeks’ gestation 
 
 
 
 
 
 
 
 
Screening test AUC DR (%) FPR (%) 
FPR = 5% FPR = 10% DR = 100% DR = 90% DR = 80% 
Small-for-gestational age <10th percentile       
Maternal characteristics and history  0.709 (0.697–0.721) 19.7 (16.6–23.1) 32.2 (28.5–36.1) 99.9 (99.8–99.9) 70.5 (69.2–71.7) 53.4 (52.0–54.8) 
HC Z-score, AC Z-score, FL Z-score 0.874 (0.865–0.883) 44.6 (40.6–48.7) 61.2 (57.1–65.1) 98.8 (98.5–99.1) 34.1 (32.8–35.5) 21.9 (20.7–23.0) 
EFW Z-score 0.876 (0.867–0.885) 46.1 (42.1–50.2) 63.1 (59.2–67.0) 93.8 (93.1–94.4) 33.8 (32.5–35.1) 21.9 (20.8–23.1) 
Maternal characteristics and history plus       
 HC Z-score, AC Z-score, FL Z-score 0.885 (0.876–0.893) 46.9 (42.9–51.0) 64.5 (60.5–68.3) 98.6 (98.3–98.9) 33.5 (32.2–34.9) 19.1 (18.0–20.3) 
 EFW Z-score 0.887 (0.879–0.895) 46.9 (42.9–51.0) 66.0 (62.0–69.7) 88.5 (87.6–89.4) 32.9 (31.6–34.02) 19.5 (18.4–20.6) 
Small-for-gestational age <5th percentile       
Maternal characteristics and history  0.734 (0.722–0.746) 22.4 (17.5–28.0) 35.7 (29.9–41.9) 98.1 (97.7–98.5) 68.8 (67.5–70.0) 49.7 (48.3–51.0) 
HC Z-score, AC Z-score, FL Z-score 0.899 (0.890–0.907) 53.2 (47.0–59.4) 65.8 (59.7–71.5) 80.0 (78.9–81.0) 26.7 (25.5–27.9) 16.9 (15.9–17.9) 
EFW Z-score 0.895 (0.887–0.903) 54.8 (48.5–60.9) 65.8 (59.7–71.5) 77.3 (76.1–78.4) 29.1 (27.8–30.3) 16.7 (15.7–17.8) 
Maternal characteristics and history plus       
 HC Z-score, AC Z-score, FL Z-score 0.908 (0.900–0.916) 54.0 (47.8–60.1) 69.2 (63.2–74.7) 84.9 (83.9–85.8) 23.0 (21.9–24.2) 13.8 (12.8–14.7) 
 EFW Z-score 0.906 (0.898–0.913) 53.6 (47.4–59.8) 70.0 (64.0–75.4) 83.4 (82.4–84.4) 25.0 (23.9–26.2) 13.5 (12.6–14.5) 
Small-for-gestational age <3rd percentile       
Maternal characteristics and history  0.772 (0.761–0.784) 24.8 (18.1–32.6) 37.6 (29.8–45.9) 90.7 (89.9–91.5) 56.3 (54.9–57.6) 41.7 (40.4–43.1) 
HC Z-score, AC Z-score, FL Z-score 0.919 (0.912–0.926) 61.1 (52.8–68.9) 73.2 (65.3–80.1) 67.4 (66.1–68.7) 20.0 (18.9–21.1) 13.7 (12.7–14.6) 
EFW Z-score 0.918 (0.911–0.925) 62.4 (54.1–70.2) 72.5 (64.6–79.5) 71.2 (69.9–72.4) 20.2 (19.1–21.3) 13.5 (12.5–14.4) 
Maternal characteristics and history plus       
 HC Z-score, AC Z-score, FL Z-score 0.928 (0.921–0.935) 64.4 (56.2–72.1) 77.2 (69.6–83.7) 63.5 (62.2–64.8) 17.4 (16.4–18.4) 10.4 (9.6–11.3) 
 EFW Z-score 0.928 (0.921–0.935) 63.8 (55.5–71.5) 77.2 (69.6–83.7) 69.3 (68.0–70.5) 19.6 (18.5–20.7) 10.6 (9.8–11.5) 
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Figure 3.2 Receiver-operating characteristic curves of maternal characteristics (black line), combination of 
maternal characteristics of HC, AC and FL z-score (blue line) and the combination of maternal characteristics 
with EFW z-score (red line) at 35-37 gestational weeks in the prediction of SGA with BW below the 10th (a), 
the 5th (b) and the 3rd (c) percentile, delivering < 2 weeks following assessment (left) or ≥37 weeks' gestation. 
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Prediction of small for gestational age delivering <2 or ≥2 weeks following 
screening at 35-37 weeks 
 
The DRs, at a FPR of 10%, of combined screening by maternal characteristics and history 
with EFW Z-scores for the prediction of SGA neonates with BW <10th, <5th and <3rd 
percentiles, delivering ≥2 weeks following assessment, were 62.6% (95% CI, 58.3-66.7; 
AUC 0.875 (95% CI, 0.866-0.884)), 67.1% (95% CI, 60.6-73.2; AUC 0.895 (95% CI, 
0.886-0.903)) and 74.4% (95% CI, 65.6-81.9; AUC 0.916 (95% CI, 0.909-0.924)), 
respectively. The performance of screening was better for the prediction of SGA delivering 
within 2 weeks of assessment with respective DRs of 87.8% (95% CI, 79.6-93.5;  
AUC 0.961 (95% CI, 0.955-0.966)), 88.7% (95% CI, 77.0-95.7; AUC 0.972 (95% CI, 
0.967-0.976)) and 91.7% (95% CI, 77.5-98.2; AUC 0.983 (95% CI, 0.979-0.986)). 
 
 
Prediction of small for gestational age delivering ≥37 weeks with screening at 35-37 
weeks compared to 30-34 weeks 
 
In combined screening by maternal characteristics and history with EFW Z-scores at  
35-37 weeks the DRs, at a FPR of 10%, of SGA neonates with BW<10th, <5th and <3rd 
percentiles delivering ≥ 37 weeks were 66.0% (95% CI, 62.0-69.7; AUC 0.887 (95% CI, 
0.879-0.895)), 70.0% (95% CI, 64-75.4; AUC 0.906 (95% CI, 0.898-0.913)) and 77.2% 
(95% CI, 69.6-83.7; AUC 0.928 (95% CI, 0.921-0.935)), respectively. Using data from a 
simultaneuos publication of colleagues, from the same Department, in combined 
screening by maternal characteristics and history with EFW Z-scores at 30-34 weeks28, 
the respective detection rates were 53.0% (95% CI, 51.3-54.8; AUC 0.833 (95% CI, 
0.829-0.837)), 58.3% (95% CI, 55.7-60.9; AUC 0.859 (95% CI, 0.855-0.863)) and 60.8% 
(95% CI, 62.6-85.0; AUC 0.875 (95% CI, 0.871-0.879)).  
 
 
3.4. DISCUSSION 
 
3.4.1. Main findings of the study 
 
The findings of this study demonstrate that the risk of delivering SGA neonates in the 
absence of PE, increases with a longer interpregnancy interval, decreases with maternal 
weight and height, it is higher in women of Afro-Caribbean or South Asian racial origin 
  68 
than in Caucasian women, in cigarette smokers, nulliparous women and in parous women 
with history of SGA. 
 
In women who deliver SGA neonates in the absence of PE, the fetal HC, AC, FL and EFW 
at 35-37 weeks’ gestation are reduced. The prediction of SGA provided by the fetal AC is 
superior to that of HC or FL, but inferior to that of the combination of the three 
measurements. The performance of screening by a combination of Z-scores for fetal HC, 
AC and FL is similar to that achieved by the EFW Z-score. 
 
Combined screening by maternal characteristics and history with EFW Z-scores at 35-37 
weeks, predicted about 70% of pregnancies that subsequently delivered SGA <5th 
neonates, at a FPR of 10%. This was superior to the DR of 58% achieved by screening at 
30-34 weeks. The performance of screening was better in the prediction of SGA delivering 
within 2 weeks of assessment, with DR of about 90%. 
 
 
3.4.2. Comparison with findings of previous studies 
 
Our findings, that the prediction of SGA neonates with BW<5th percentile at 35-37 
gestational weeks by sonographic estimation of EFW Z-scores is superior to that of 
screening at 30-34 weeks (70% vs 58%), at a FPR of 10%, are similar to those of a 
previous study that reported rates of 75% and 58% with screening at 34-37 weeks and 30-
33 weeks, respectively27. In the latter study, all cases of SGA were included, whereas is 
this study, the cases with associated PE were excluded. 
 
A routine third trimester scan is by far superior to the traditional approach of abdominal 
palpation in identifying pregnancies at high-risk of delivering SGA neonates. A population 
based observational study of 6318 consecutive low risk singleton pregnancies reported 
that abdominal palpation predicted only 21% and 28% of SGA neonates with birth weight 
<10th and 2.3rd percentiles respectively, at FPR of about 5%20. One randomized study 
compared the effectiveness of abdominal palpation to that of serial measurements of 
symphysial-fundal height in the prediction of SGA neonates with birth weight <10th 
percentile and reported no significant difference between the two methods (28% vs. 48%, 
both at FPR of about 4%)21.  
 
The advantage of using Bayes theorem to combine the prior risk from maternal 
characteristics and medical history with fetal biometry is that individual patient-specific 
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risks and the performance of screening for SGA of different severities, delivering at term, 
can be estimated. This is an essential first step for establishing patient management 
protocols. 
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biometry, uterine artery Doppler and mean 
arterial blood pressure at 35-37 weeks 
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Chapter 4: Screening by maternal characteristics, fetal biometry, uterine 
artery Doppler and mean arterial blood pressure at 35-37 weeks 
 
 
ABSTRACT 
 
Objective: To investigate the potential value of uterine artery pulsatility index (PI) and 
mean arterial pressure (MAP) at 35-37 weeks’ gestation in the prediction of delivery of 
small for gestational age (SGA) neonates, in the absence of preeclampsia (PE). 
 
Methods: Screening study in singleton pregnancies at 35-37 weeks, including 245 that 
delivered SGA neonates with birth weight <5th percentile and 4,876 cases unaffected by 
SGA, PE or gestational hypertension (normal group). Multivariable logistic regression 
analysis was used to determine if uterine artery PI and MAP improved the prediction of 
SGA neonates provided by screening with maternal characteristics and medical history 
(maternal factors) and estimated fetal weight (EFW) from fetal head circumference, 
abdominal circumference and femur length.  
  
Results: In the SGA<5th group, compared to the normal group, the median multiple of the 
median (MoM) values of uterine artery PI and MAP were significantly higher. Combined 
screening by maternal factors, EFW Z-score, uterine artery PI and MAP at 35-37 weeks, 
predicted at 10% false positive rate, 90%, 86% and 90% of SGA neonates with birth 
weight <10th, <5th and <3rd percentiles, respectively, delivering at <2 weeks following 
assessment and the respective values for SGA delivering at >37 weeks were 66%, 74% 
and 80%. Such performance was not significantly different from screening by maternal 
factors and EFW Z-score alone. 
 
Conclusion: Addition of uterine artery PI and MAP to combined testing using maternal 
factors and fetal biometry at 35-37 weeks does not improve the performance of screening 
for delivery of SGA neonates. 
 
 
This chapter is based on: Fadigas C, Guerra L, Garcia-Tizon Larroca S, Poon LC and 
Nicolaides KH. Prediction of small-for-gestational age neonates: screening by uterine 
artery Doppler and mean arterial pressure at 35-37 weeks. Ultrasound Obstet and 
Gynecol 2015; 45: 715-21. 
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4.1. INTRODUCTION 
 
Small for gestational age (SGA) neonates are at increased risk of perinatal mortality and 
morbidity, but the risks can be substantially reduced if the condition is identified prenatally, 
because in such cases close monitoring and appropriate timing of delivery and prompt 
neonatal care can be undertaken110. The traditional approach of identifying pregnancies 
with SGA fetuses is maternal abdominal palpation and serial measurements of 
symphysial-fundal height, but the detection rate (DR) of this approach is less that 30%20,21. 
A higher performance in screening for SGA is achieved by a third-trimester assessment 
which includes ultrasound examination for fetal biometry and the timing of such 
assessment, at 32 or 36 weeks’ gestation, could be defined by the results of assessment 
at 22 weeks187, 188.  
 
Screening by a combination of maternal characteristics and medical history with estimated 
fetal weight (EFW), uterine artery (UtA) pulsatility index (PI) and mean arterial pressure 
(MAP) at 32 weeks’ gestation, predicted, at false positive rate (FPR) of 10%, 83%, 91% 
and 93%, of SGA neonates delivering within five weeks of assessment with respective 
birth weight <10th, <5th and <3rd percentiles in the absence of preeclampsia (PE)189. 
However, the respective values for delivery at >5 weeks of assessment were only 53%, 
60% and 63%.  
 
 
4.1.1. Objectives 
 
The objectives of this study in singleton pregnancies undergoing routine antenatal 
assessment at 35-37 weeks’ gestation are firstly, to investigate the potential value of 
uterine artery PI and MAP on their own and in combination with maternal characteristics, 
medical history and EFW in the prediction of delivery of SGA neonates in the absence of 
PE and secondly, to develop specific algorithms for the calculation of patient-specific risks 
for SGA.  
 
 
4.2. METHODS 
 
The data for this study were derived from prospective screening for adverse obstetric 
outcomes in women attending for their routine hospital visit in the third trimester of 
pregnancy at 35-37 weeks’ gestation. The methodology for recording of patient 
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characteristics, sonographic estimation of EFW, UtA PI, MAP, serum metabolites, 
outcome measures and statistical analysis was as described in Chapter 2.  
 
 
4.3. RESULTS 
The characteristics of the study population of 5121 pregnancies, including 245 delivering 
SGA <5th neonates in the absence of PE, are presented in Table 4.1.  
 
Table 4.1. Characteristics of the study population of women with a singleton pregnancy with normal outcome 
or with a small-for-gestational-age (SGA) neonate, in the absence of pre-eclampsia (PE). 
 
 
SLE = systemic lupus erythematosus; APLS = antiphospholipid syndrome; IQR = interquartile range; PE = preeclampsia; 
SGA = small for gestational age 
 
Characteristic Normal 
(n=4876) 
SGA without PE 
(n=245) 
P-value 
Maternal age in years, median (IQR) 31.2 (26.5-35.0) 30.1 (24.6-35.3) 0.061 
Maternal weight in Kg, median (IQR) 79.0 (70.8-89.8) 73.5 (63.9-84.1) <0.0001 
Maternal height in cm, median (IQR) 164 (160-168) 162 (158-165) <0.0001 
Gestation at screening in weeks, median (IQR) 36.1 (36.0-36.4) 36.3 (36.0-36.4) 0.848 
Racial origin    
   Caucasian, n (%) 3495 (71.7) 140 (57.1) <0.0001 
   Afro-Caribbean, n (%) 941 (19.3) 57 (23.3) 0.137 
   South Asian, n (%) 178 (3.7) 30 (12.2) <0.0001 
   East Asian, n (%) 101 (2.1) 6 (2.4) 0.644 
   Mixed, n (%) 161 (3.3) 12 (4.9) 0.200 
Past obstetric history    
   Nulliparous, n (%) 2352 (48.2) 148 (60.4) 0.0002 
   Parous with no prior PE and SGA, n (%) 2318 (47.5) 67 (27.3) <0.0001 
   Parous with prior PE no SGA, n (%) 77 (1.6) 4 (1.6) 0.795 
   Parous with prior SGA no PE, n (%) 121 (2.5) 25 (10.2) <0.0001 
   Parous with prior SGA and PE, n (%) 8 (0.2) 1 (0.4) 0.357 
Inter-pregnancy interval in years, median (IQR) 3.1 (2.1-5.1) 2.9 (2.1-5.5) 0.965 
Cigarette smoker, n (%) 464 (9.5) 59 (24.1) <0.0001 
Conception    
   Spontaneous, n (%) 4758 (97.6) 235 (95.9) 0.136 
   Ovulation drugs, n (%) 20 (0.4) 2 (0.8) 0.284 
   In vitro fertilization, n (%) 98 (2.0) 8 (3.3) 0.167 
Chronic hypertension 64 (1.3) 2 (0.8) 0.770 
Pre-existing diabetes mellitus, n (%) 57 (1.2) 2 (0.8) >0.999 
   Type 1, n (%) 27 (0.6) 1 (0.4) >0.999 
   Type 2, n (%) 30 (0.6) 1 (0.4) >0.999 
SLE / APLS, n (%) 13 (0.3) 0 (0.0) >0.999 
Gestation at delivery in weeks, median (IQR) 40.0 (39.1-40.9) 39.4 (38.6-40.4) <0.0001 
Birth weight in grams, median (IQR) 3435 (3,140-3,745) 2550 (2,350-2,718) <0.0001 
Birth weight in percentile, median (IQR) 50.6 (26.8-75.6) 2.7 (1.2-3.8) <0.0001 
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4.3.1. Normal pregnancy outcome 
 
In the unaffected pregnancies with birth weight ≥5th percentile, the mean ± SD, 90th and 
95th percentile of log10 MoM UtA PI were -0.009 ± 0.113, 0.134 and 0.187, respectively. 
The mean ± SD, 90th and 95th percentile of log10 MoM MAP were 0.002 ± 0.033, 0.044 and 
0.056, respectively (Table 4.2). There was no significant association between log10 MoM 
values of UtA PI and MAP (r=-0.004, P=0.893). There was a significant inverse 
association between log10 MoM UtA PI with assessment to delivery interval (r=-0.096, 
P<0.0001) and birth weight Z-score (r=-0.096, P<0.0001), and between log10 MoM MAP 
with assessment to delivery interval (r=-0.080, P<0.0001) but not birth weight Z-score  
(r=-0.022, P=0.113). 
 
 
 
Table 4.2 Uterine artery pulsatility index (UtA-PI) and mean arterial pressure (MAP) at 35–37 
weeks’ gestation in pregnancies that delivered small-for-gestational-age (SGA) neonates with birth 
weight < 5th percentile, in the absence of pre-eclampsia, and in unaffected pregnancies 
 
Outcome 
group 
Median 
(IQR) 
MoM  
(median (IQR)) 
Log10 MoM 
(mean ± SD) 
> 95th percentile  
(n (%, 95% CI)) 
> 90th percentile  
(n (%, 95% CI)) 
UtA-PI 
Normal 
0.690 
(0.590–0.820) 
0.967 
(0.824–1.146) 
–0.009 ± 0.113 243  
(5.0, 4.4–5.6) 
487 
(10.0, 9.2–10.9) 
SGA 
0.785 
(0.620–0.978)* 
1.104 
(0.873–1.385)* 
0.050 ± 0.137* 42 
(17.1, 12.9–22.4)* 
65 
(26.5, 21.4–32.4)* 
MAP 
Normal 
89.0 
(83.9–93.8) 
1.008 
(0.955–1.059) 
0.002 ± 0.033 243 
(5.0, 4.4–5.6) 
487 
(10.0, 9.2–10.9) 
SGA 
90.3 
(85.2–95.6)* 
1.045 
(0.969–1.101)* 
0.014 ± 0.037* 25 
(10.2, 7.0–14.6)* 
53 
(21.6, 16.9–27.2)* 
 
Comparison between normal outcome and SGA by Chi square test or Fisher’s exact test for 
categorical variables and Mann–Whitney U-test or student’s t-test for continuous 
variables:*P < 0.05. IQR, interquartile range, MoM, multiples of the unaffected median. 
 
 
 
 
4.3.2. Small for gestational age  
 
In the SGA<5th group, compared to the normal group, the median MoM values of uterine 
artery PI and MAP at 35-37 weeks were significantly higher (Table 4.2). There was no 
significant association between log10 MoM values of uterine artery PI and MAP (r=0.109, 
P=0.088). There was a significant inverse association between log10 MoM uterine artery 
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PI with assessment to delivery interval (r=-0.232, P<0.0001; Figure 4.1.a) and birth weight 
Z-score (r=-0.157, P=0.011; Figure 4.1.b). There was no significant association between 
log10 MoM MAP with assessment to delivery interval (r=-0.100, P=0.107; Figure 4.1.c) and 
birth weight Z-score (r=-0.057, P=0.354; Figure 4.1.d).  
 
 
 
Figure 4.1 Log10 uterine artery pulsatility index (UtA-PI) (A, B) and log10 mean arterial pressure (MAP) (C, D) 
multiples of median according to assessment-to-delivery interval (A, C) and birth-weight Z-score (B, D) in 
pregnancies delivering small-for-gestational-age neonates with birth weight < 5th percentile, plotted on the 
50th (solid line), 90th and 95th (dashed line) percentile of the appropriate normal range. 
 
 
Multivariable logistic regression analysis demonstrated that in the prediction of SGA <5th 
there were significant contributions from maternal characteristics, EFW Z-score, uterine 
artery PI and MAP (Table 4.3). Combined screening by maternal characteristics and 
history with EFW Z-scores, uterine artery PI and MAP detected 66%, 74% and 80% of 
SGA neonates with birth weight <10th, <5th and <3rd percentiles, respectively, at 10% FPR.  
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Table 4.3 Fitted regression models with maternal characteristics and history, estimated fetal weight 
(EFW) Z-score, uterine artery pulsatility index (UtA-PI) and mean arterial pressure (MAP) at 35–37 
weeks’ gestation for the prediction of small-for-gestational-age neonates with birth weight < 5th 
percentile, in the absence of pre-eclampsia 
 
 
The areas under ROC (AUC), the detection rates (DRs) at FPRs of 5% and 10% and 
FPRs for DRs of 100%, 90% and 80% of SGA <10th, SGA <5th and SGA <3rd delivering at 
<2 weeks of assessment and at >37 weeks’ gestation in screening by maternal 
characteristics, EFW Z-score, uterine artery PI, MAP and their combination are given in 
 Table 4.4, 4.5 and 4.6 and Figure 4.2. 
Independent 
variable 
Coefficient SE OR 95% CI P 
Maternal characteristics and history with UtA-PI (R2 = 0.140, P < 0.0001) 
Intercept –0.14600 0.21172 - - - 
Logit (a-priori risk) 2.35253 0.17513 10.512 7.458–14.817 < 0.0001 
Log10 MoM UtA-PI 2.78497 0.60186 16.199 4.980–52.699 < 0.0001 
Log10 MoM UtA-PI2 7.78026 2.65846 2.39 x 103 1.31 x 101 to 4.38 x 105 0.003 
Maternal characteristics and history with MAP (R2 = 0.122, P < 0.0001) 
Intercept –0.19178 0.21290 - - - 
Logit (a-priori risk) 2.29773 0.17204 9.952 7.103–13.942 < 0.0001 
Log10 MoM MAP 7.24939 1.85688 1.41 x 103 3.70 x 101 to 5.36 x 104 < 0.0001 
Log10 MoM MAP2 86.92506 32.41269 5.64 x 1037 1.45 x 1010 to 2.19 x 1065 0.007 
Maternal characteristics and history with UtA-PI and MAP (R2 = 0.157, P < 0.0001) 
Intercept –0.32312 0.22619 - - - 
Logit (a-priori risk) 2.34318 0.18198 10.414 7.290–14.878 < 0.0001 
Log10 MoM UtA-PI 3.00152 0.63232 20.116 5.825–69.466 < 0.0001 
Log10 MoM UtA-PI2 6.37356 2.76860 5.86 x 102 2.58 to 1.33 x 105 0.021 
Log10 MoM MAP 6.98422 1.96456 1.08 x 103 2.30 x 101 to 5.08 x 104 0.0004 
Log10 MoM MAP2 80.60922 34.82041 1.02 x 1035 2.34 x 105 to 4.44 x 1064 0.021 
Maternal characteristics and history with EFW and UtA-PI (R2 = 0.410, P < 0.0001) 
Intercept –1.99167 0.27112 - - - 
Logit (a-priori risk) 1.32430 0.20436 3.760 2.519–5.612 < 0.0001 
EFW Z-score –2.49459 0.13358 0.083 0.064–0.107 < 0.0001 
Log10 MoM UtA-PI 1.58376 0.66640 4.873 1.320–17.991 0.017 
Log10 MoM UtA-PI2 7.22373 3.02151 1.37 x 103 3.68 to 5.12 x 105 0.017 
Maternal characteristics and history with EFW and MAP (R2 = 0.408, P < 0.0001) 
Intercept –2.09259 0.27670 - - - 
Logit (a-priori risk) 1.23907 0.20366 3.452 2.316–5.146 < 0.0001 
EFW Z-score –2.53483 0.13339 0.079 0.061–0.103 < 0.0001 
Log10 MoM MAP 5.57999 2.11732 2.65 x 102 4.18 to 1.68 x 104 0.008 
Log10 MoM MAP2 79.80021 40.15720 4.54 x 1034 2.98 to 6.90 x 1068 0.047 
Maternal characteristics and history with EFW, UtA-PI and MAP (R2 = 0.413, P < 0.0001) 
Intercept –1.95863 0.27992 - - - 
Logit (a-priori risk) 1.31289 0.21184 3.717 2.454–5.630 < 0.0001 
EFW Z-score –2.48639 0.13877 0.083 0.063–0.109 < 0.0001 
Log10 MoM UtA-PI 2.48618 0.63132 12.015 3.486–41.410 < 0.0001 
Log10 MoM MAP 5.90022 2.27286 3.65 x 102 4.24 to 3.14 x 104 0.009 
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Table 4.4. Performance of screening for small for gestational age neonates with birth weight <10th, <5th and <3rd percentile delivering within two weeks of 
assessment and at >37 weeks’ gestation in the absence of preeclampsia, with maternal factors, estimated fetal weight, uterine artery pulsatility index and 
mean arterial pressure at 35-37 weeks’ gestation.  
 
Values in parenthesis are 95% CIs. AUC, area under receiver operating characteristic curve. FPR, false positive rate. DR, detection rate. 
  
Screening test AUC curve 
DR (%) FPR (%) 
FPR 5% FPR 10% DR 100% DR 90% DR 80% 
Delivery within 2 weeks       
SGA <10th percentile       
Maternal factors  0.744 (0.731-0.756) 25.9 (16.8-36.9) 40.7 (29.9-52.2) 79.8 (78.6-80.9) 64.4 (63.0-65.7) 48.6 (47.2-50.1) 
Maternal factors, EFW 0.961 (0.955-0.967) 77.8 (67.2-86.3) 86.4 (79.6-93.5) 53.4 (51.9-54.8) 11.6 (10.7-12.6) 5.6 (5.0-6.3) 
Maternal factors, EFW, UtA PI, MAP 0.963 (0.957-0.968) 76.5 (65.8-85.2) 90.1 (81.5-95.6) 51.2 (49.8-52.7) 9.3 (8.4-10.1) 5.7 (5.0-6.4) 
SGA <5th percentile       
Maternal factors  0.800 (0.788-0.811) 34.1 (20.5-49.9) 50.0 (34.6-65.4) 73.5 (72.2-74.7) 57.6 (56.2-59.0) 44.7 (43.3-46.1) 
Maternal factors, EFW 0.969 (0.964-0.974) 84.1 (69.9-93.4) 86.4 (72.6-94.8) 34.0 (32.7-35.4) 13.4 (12.5-14.4) 3.6 (3.1-4.1) 
Maternal factors, EFW, UtA PI, MAP 0.972 (0.967-0.976) 84.1 (69.9-93.4) 86.4 (72.6-94.8) 34.3 (32.9-35.6) 12.0 (11.1-12.9) 3.0 (2.6-3.6) 
SGA <3rd percentile       
Maternal factors  0.813 (0.802-0.824) 36.7 (19.9-56.1) 50.0 (32.9-67.1) 60.2 (58.8-61.6) 52.8 (51.4-54.2) 38.1 (37.7-39.4) 
Maternal factors, EFW 0.982 (0.978-0.985) 90.0 (73.5-97.9) 90.0 (73.5-97.9) 16.7 (15.6-17.7) 3.6 (3.1-4.1) 0.9 (0.7-1.2) 
Maternal factors, EFW, UtA PI, MAP 0.985 (0.981-0.988) 90.0 (73.5-97.9) 90.0 (73.5-97.9) 13.1 (12.2-14.1) 2.8 (2.4-3.3) 0.6 (0.4-0.9) 
Delivery at >37 weeks       
SGA <10th percentile       
Maternal factors  0.712 (0.700-0.725) 20.1 (16.8-23.7) 33.2 (29.2-37.3) 98.6 (98.2-98.9) 69.9 (68.5-71.2) 53.5 (52.0-54.9) 
Maternal factors, EFW 0.887 (0.878-0.896) 47.3 (43.1-51.6) 66.1 (62.0-70.1) 82.5 (81.3-83.6) 32.6 (31.3-34.0) 20.2 (19.0-21.4) 
Maternal factors, EFW, UtA PI, MAP 0.888 (0.879-0.897) 48.6 (44.3-52.9) 66.1 (62.0-70.1) 84.8 (83.7-85.8) 31.4 (30.1-32.8) 19.1 (18.0-20.3) 
SGA <5th percentile       
Maternal factors  0.741 (0.729-0.753) 23.5 (18.2-29.5) 38.0 (31.8-44.6) 98.1 (97.7-98.5) 68.6 (67.3-69.9) 48.8 (47.4-50.2) 
Maternal factors, EFW 0.908 (0.900-0.916) 54.3 (47.7-60.8) 71.4 (65.1-77.1) 83.5 (82.4-84.5) 24.6 (23.4-25.8) 13.4 (12.5-14.4) 
Maternal factors, EFW, UtA PI, MAP 0.910 (0.902-0.917) 55.6 (48.9-62.0) 73.9 (67.8-79.4) 83.2 (82.1-84.2) 25.2 (24.0-26.5) 14.1 (13.1-15.1) 
SGA <3rd percentile       
Maternal factors  0.775 (0.764-0.787) 26.2 (18.8-34.6) 39.2 (30.8-48.2) 90.8 (90.0-91.6) 53.4 (52.0-54.8) 41.4 (40.0-42.8) 
Maternal factors, EFW 0.929 (0.922-0.936) 64.6 (55.5-71.5) 79.2 (71.2-85.8) 69.1 (67.8-70.4) 17.8 (16.7-18.9) 10.1 (9.3-11.0) 
Maternal factors, EFW, UtA PI, MAP 0.929 (0.921-0.936) 64.6 (55.8-72.8) 80.0 (72.1-86.5) 70.2 (68.9-71.4) 20.1 (19.0-21.3) 9.9 (9.0-10.7) 
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Table 4.5. Detection rates (DR) in screening for small-for-gestational-age (SGA) neonates with birth weight < 10th, < 5th and < 3rd percentile, delivering within 2 
weeks of assessment, in the absence of pre-eclampsia, using maternal factors, estimated fetal weight (EFW), uterine artery pulsatility index (UtA-PI) and 
mean arterial pressure (MAP) at 35–37 weeks’ gestation 
Screening test AUC DR (%) FPR (%) 
FPR = 5% FPR = 10% DR = 100% DR = 90% DR = 80% 
SGA < 10th percentile       
Maternal factors  0.744 (0.731-0.756) 25.9 (16.8-36.9) 40.7 (29.9-52.2) 79.8 (78.6-80.9) 64.4 (63.0-65.7) 48.6 (47.2-50.1) 
Maternal factors plus       
      EFW Z-score 0.961 (0.955-0.967) 77.8 (67.2-86.3) 86.4 (79.6-93.5) 53.4 (51.9-54.8) 11.6 (10.7-12.6) 5.6 (5.0-6.3) 
      UtA-PI 0.798 (0.787-0.810) 34.6 (24.3-46.0) 45.7 (34.6-57.1) 84.3 (83.2-85.3) 61.6 (60.2-63.1) 39.3 (37.9-40.8) 
      MAP 0.743 (0.731-0.756) 33.3 (23.2-44.7) 42.0 (31.1-53.5) 81.9 (80.7-83.0) 64.7 (63.3-66.1) 52.1 (50.6-53.6) 
      UtA-PI and MAP 0.795 (0.783-0.807) 22.3 (18.6-26.1) 32.4 (28.2-36.8) 86.6 (85.6-87.6) 54.6 (53.1-56.0) 34.9 (33.5-36.3) 
Maternal factors and EFW plus       
      UtA-PI 0.965 (0.959-0.970) 77.8 (67.2-86.3) 87.7 (78.5-93.9) 46.3 (44.8-47.7) 10.5 (9.7-11.5) 5.4 (4.8-6.2) 
      MAP 0.958 (0.952-0.964) 76.5 (65.8-85.2) 87.7 (78.5-93.9) 56.9 (55.5-58.3) 12.2 (11.3-13.2) 6.6 (5.9-7.4) 
      UtA-PI and MAP 0.963 (0.957-0.968) 76.5 (65.8-85.2) 90.1 (81.5-95.6) 51.2 (49.8-52.7) 9.3 (8.4-10.1) 5.7 (5.0-6.4) 
SGA < 5th percentile       
Maternal  factors 0.800 (0.788-0.811) 34.1 (20.5-49.9) 50.0 (34.6-65.4) 73.5 (72.2-74.7) 57.6 (56.2-59.0) 44.7 (43.3-46.1) 
Maternal  factors plus       
      EFW Z-score 0.969 (0.964-0.974) 84.1 (69.9-93.4) 86.4 (72.6-94.8) 34.0 (32.7-35.4) 13.4 (12.5-14.4) 3.6 (3.1-4.1) 
      UtA-PI 0.866 (0.856-0.875) 47.7 (32.5-63.3) 59.1 (43.2-73.7) 69.3 (67.9-70.6) 42.0 (40.6-43.4) 22.1 (20.9-23.4) 
      MAP 0.804 (0.793-0.815) 45.5 (30.4-61.2) 54.6 (38.8-69.6) 81.3 (80.1-82.3) 59.6 (58.2-61.0) 46.5 (45.1-47.9) 
      UtA-PI and MAP 0.860 (0.850-0.870) 43.2 (28.3-59.0) 59.1 (43.2-73.7) 73.6 (72.3-74.8) 35.3 (34.0-36.7) 25.5 (24.3-26.8) 
Maternal  factors and EFW plus       
      UtA-PI 0.971 (0.966-0.975) 84.1 (69.9-93.4) 86.4 (72.6-94.8) 31.7 (30.4-33.1) 13.1 (12.2-14.1) 3.5 (3.0-4.1) 
      MAP 0.968 (0.962-0.972) 84.1 (69.9-93.4) 86.4 (72.6-94.8) 38.0 (36.6-39.4) 10.8 (10.0-11.7) 3.3 (2.8-3.8) 
      UtA-PI and MAP 0.972 (0.967-0.976) 84.1 (69.9-93.4) 86.4 (72.6-94.8) 34.3 (32.9-35.6) 12.0 (11.1-12.9) 3.0 (2.6-3.6) 
SGA < 3rd percentile       
Maternal factors  0.813 (0.802-0.824) 36.7 (19.9-56.1) 50.0 (32.9-67.1) 60.2 (58.8-61.6) 52.8 (51.4-54.2) 38.1 (37.7-39.4) 
Maternal  factors plus       
      EFW Z-score 0.982 (0.978-0.985) 90.0 (73.5-97.9) 90.0 (73.5-97.9) 16.7 (15.6-17.7) 3.6 (3.1-4.1) 0.9 (0.7-1.2) 
      UtA-PI 0.875 (0.866-0.884) 50.0 (32.4-67.6) 60.0 (40.6-77.3) 63.0 (61.6-64.4) 27.2 (26.0-28.5) 18.6 (17.5-19.7) 
      MAP 0.823 (0.812-0.833) 50.0 (31.9-68.1) 56.7 (37.4-74.5) 69.5 (68.2-70.8) 54.7 (53.3-56.1) 43.7 (42.4-45.1) 
      UtA-PI and MAP 0.873 (0.863-0.882) 46.7 (28.3-65.7) 63.3 (43.9-80.1) 69.1 (67.8-70.4) 33.9 (32.6-35.2) 25.5 (24.3-26.8) 
Maternal  factors and EFW plus       
      UtA-PI 0.984 (0.980-0.987) 90.0 (73.5-97.9) 90.0 (73.5-97.9) 13.8 (12.8-14.8) 2.7 (2.3-3.2) 0.5 (0.4-0.8) 
      MAP 0.981 (0.977-0.985) 90.0 (73.5-97.9) 90.0 (73.5-97.9) 20.0 (18.9-21.2) 2.6 (2.2-3.1) 0.9 (0.7-1.2) 
      UtA-PI and MAP 0.985 (0.981-0.988) 90.0 (73.5-97.9) 90.0 (73.5-97.9) 13.1 (12.2-14.1) 2.8 (2.4-3.3) 0.6 (0.4-0.9) 
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Table 4.6. Detection rates (DR) in screening for small-for-gestational-age (SGA) neonates with birth weight < 10th, < 5th and < 3rd percentile, delivering ≥ 37 
weeks, in the absence of pre-eclampsia, using maternal factors, estimated fetal weight (EFW), uterine artery pulsatility index (UtA-PI) and mean arterial 
pressure (MAP) at 35–37 weeks’ gestation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screening test AUC curve DR (%) FPR (%) 
FPR 5% FPR 10% DR 100% DR 90% DR 80% 
SGA <10th percentile       
Maternal factors  0.712 (0.700–0.725) 20.1 (16.8–23.7) 33.2 (29.2–37.3) 98.6 (98.2–98.9) 69.9 (68.5–71.2) 53.5 (52.0–54.9) 
Maternal factors plus       
      EFW Z-score 0.887 (0.878–0.896) 47.3 (43.1–51.6) 66.1 (62.0–70.1) 82.5 (81.3–83.6) 32.6 (31.3–34.0) 20.2 (19.0–21.4) 
      UtA-PI 0.725 (0.713–0.738) 23.4 (19.9–27.2) 33.7 (29.7–37.9) 99.0 (98.7–99.3) 68.8 (67.4–70.1) 50.4 (48.9–51.8) 
      MAP 0.719 (0.707–0.731) 21.2 (17.8–24.9) 32.4 (28.5–36.5) 99.1 (98.8–99.3) 69.8 (68.5–71.2) 52.3 (50.9–53.8) 
      UtA-PI and MAP 0.728 (0.716–0.740) 23.9 (20.4–27.8) 34.1 (30.1–38.2) 99.3 (99.0–99.5) 69.1 (67.7–70.4) 49.6 (48.1–51.1) 
Maternal factors and EFW plus       
      UtA-PI 0.889 (0.880–0.897) 47.5 (43.2–51.8) 66.3 (62.1–70.3) 84.0 (82.9–85.0) 31.8 (30.5–33.2) 18.7 (17.6–19.8) 
      MAP 0.888 (0.879–0.896) 47.0 (42.7–51.3) 66.5 (62.3–70.3) 84.5 (83.4–85.6) 32.5 (31.2–33.9) 19.2 (18.0–20.3) 
      UtA-PI and MAP 0.888 (0.879–0.897) 48.6 (44.3–52.9) 66.1 (62.0–70.1) 84.8 (83.7–85.8) 31.4 (30.1–32.8) 19.1 (18.0–20.3) 
SGA <5th percentile       
Maternal factors  0.741 (0.729–0.753) 23.5 (18.2–29.5) 38.0 (31.8–44.6) 98.1 (97.7–98.5) 68.6 (67.3–69.9) 48.8 (47.4–50.2) 
Maternal factors plus       
      EFW Z-score 0.908 (0.900–0.916) 54.3 (47.7–60.8) 71.4 (65.1–77.1) 83.5 (82.4–84.5) 24.6 (23.4–25.8) 13.4 (12.5–14.4) 
      UtA-PI 0.762 (0.751–0.774) 28.2 (22.5–34.4) 39.3 (33.0–45.9) 98.7 (98.4–99.0) 61.8 (60.5–64.4) 44.0 (42.6–45.4) 
      MAP 0.756 (0.744–0.768) 26.1 (20.6–32.2) 39.3 (33.0–45.9) 97.2 (96.7–97.6) 65.3 (64.0–66.6) 45.2 (46.6–43.8) 
      UtA-PI and MAP 0.770 (0.758–0.781) 28.6 (22.9–34.9) 41.5 (35.1–48.1) 94.1 (93.4–94.7) 61.9 (60.6–63.3) 43.8 (42.4–45.2) 
Maternal factors and EFW plus       
      UtA-PI 0.909 (0.901–0.917) 56.4 (49.8–62.9) 70.9 (64.7–76.7) 82.2 (81.1–83.3) 22.5 (21.3–23.7) 13.8 (13.9–14.8) 
      MAP 0.910 (0.902–0.918) 57.3 (50.7–63.7) 69.7 (63.3–75.5) 85.5 (84.5–86.5) 21.4 (20.2–22.6) 13.1 (12.2–14.1) 
      UtA-PI and MAP 0.910 (0.902–0.917) 55.6 (48.9–62.0) 73.9 (67.8–79.4) 83.2 (82.1–84.2) 25.2 (24.0–26.5) 14.1 (13.1–15.1) 
SGA <3rd percentile       
Maternal factors  0.775 (0.764–0.787) 26.2 (18.8–34.6) 39.2 (30.8–48.2) 90.8 (90.0–91.6) 53.4 (52.0–54.8) 41.4 (40.0–42.8) 
Maternal factors plus       
      EFW Z-score 0.929 (0.922–0.936) 64.6 (55.5–71.5) 79.2 (71.2–85.8) 69.1 (67.8–70.4) 17.8 (16.7–18.9) 10.1 (9.3–11.0) 
      UtA-PI 0.797 (0.786–0.808) 30.0 (22.3–38.7) 40.8 (32.2–49.7) 87.8 (86.8–88.7) 53.3 (51.9–54.7) 33.4 (32.1–34.8) 
      MAP 0.791 (0.779–0.802) 30.8 (23.0–39.5) 42.3 (33.7–51.3) 86.5 (86.5–87.5) 57.0 (55.6–58.4) 35.9 (34.6–37.3) 
      UtA-PI and MAP 0.804 (0.793–0.815) 33.1 (25.1–41.9) 43.9 (35.2–52.8) 84.2 (83.2–85.2) 52.1 (50.7–53.5) 33.2 (31.9–34.5) 
Maternal factors and EFW plus       
      UtA-PI 0.929 (0.921–0.936) 66.2 (57.3–74.2) 79.2 (71.2–85.8) 68.3 (67.0–69.6) 21.0 (19.9–22.2) 10.1 (9.3–11.0) 
      MAP 0.930 (0.923–0.937) 66.9 (58.1–74.9) 76.9 (68.7–83.9) 71.5 (70.2–72.7) 20.0 (18.9–21.1) 10.9 (10.0–11.7) 
      UtA-PI and MAP 0.929 (0.921–0.936) 64.6 (55.8–72.8) 80.0 (72.1–86.5) 70.2 (68.9–71.4) 20.1 (19.0–21.3) 9.9 (9.0–10.7) 
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             (a. <10th)         (b. <5th)          (c. <3rd) 
 
Figure 4.2. Receiver–operating characteristics curves of maternal factors (black) and maternal 
factors with uterine artery pulsatility index (red), mean arterial pressure (blue), estimated fetal 
weight Z-score (green) and their combination (purple), at 35–37 weeks' gestation, in the prediction 
of small-for-gestational-age neonates with birth weight < 10th (a), < 5th (b) or < 3rd (c) percentile, 
delivering < 2 weeks following assessment (top) or ≥ 37 weeks' gestation (bottom). 
 
The DRs, at FPR of 10%, of combined screening by maternal characteristics and history 
with EFW Z-scores for the prediction of SGA neonates with birth weight <10th, <5th and 
<3rd percentiles, delivering at <2 weeks of assessment, were 86.4% (95% CI, 79.6-93.5%; 
AUC 0.961 (95% CI, 0.955-0.967)), 86.4% (95% CI, 72.6-94.8; AUC 0.969 (95% CI, 
0.964-0.974)) and 90.0% (95% CI, 73.5-97.9; AUC 0.982 (95% CI, 0.978-0.985)), 
respectively. The respective values for SGA delivering at >37 weeks, were 66.1% (95% 
CI, 62.0-70.1; AUC 0.887 (95% CI, 0.878-0.896)), 71.4% (95% CI, 65.1-77.1; AUC 0.908 
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(95% CI, 0.900-0.916)) and 79.2% (95% CI, 71.2-85.8; AUC 0.929 (95% CI, 0.922-
0.936)). 
 
In combined screening by maternal characteristics and history with EFW Z-scores, UtA PI 
and MAP at 35-37 weeks’ gestation, the DRs, at FPR of 10%, of SGA neonates with birth 
weight <10th, <5th and <3rd percentiles delivering at <2 weeks of assessment were 90.1% 
(95% CI, 81.5-95.6; AUC 0.963 (95% CI, 0.957-0.968)), 86.4% (95% CI, 72.6-94.8; AUC 
0.972 (95% CI, 0.967-0.976)) and 90.0% (95% CI, 73.5-97.9; AUC 0.985 (95% CI, 0.981-
0.988)), respectively. The respective values for SGA delivering at >37 weeks, were 66.1% 
(95% CI, 62.0-70.1; AUC 0.888 (95% CI, 0.879-0.897)), 73.9% (95% CI, 67.8-79.4; AUC 
0.910 (95% CI, 0.902-0.917)) and 80.0% (95% CI, 72.1-86.5; AUC 0.929 (95% CI, 0.921-
0.936)). 
 
 
 
 
4.4. DISCUSSION 
 
4.4.1. Main findings of the study 
 
The findings of the study demonstrate that in women who deliver SGA neonates in the 
absence of PE, uterine artery PI and MAP at 35-37 weeks’ gestation are increased and 
EFW is reduced. The deviation from normal for uterine artery PI is inversely related to the 
severity of the disease reflected in the gestational age at delivery and the birth weight Z-
score. 
 
Combined screening by maternal factors, EFW Z-score, uterine artery PI and MAP at 35-
37 weeks, predicted, at FPR of 10%, 90%, 86% and 90% of SGA neonates with birth 
weight <10th, <5th and <3rd percentiles delivering at <2 weeks of assessment and the 
respective values for SGA delivering at >37 weeks were 66%, 74% and 80%. The addition 
of uterine artery PI and MAP at 35-37 weeks does not improve the performance of 
screening for delivery of SGA neonates achieved by combined testing using maternal 
factors and fetal biometry alone. 
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4.4.2. Comparison with findings from previous studies 
 
Previous studies examining pregnancies with SGA fetuses in the third-trimester reported 
that the outcome was worse in cases with Doppler evidence of increased, rather than 
normal impedance to flow in the uterine arteries145, 190. 
 
A screening study involving 1848 singleton pregnancies at 30-32 weeks’ gestation 
reported that uterine artery PI improved the prediction of SGA neonates provided by fetal 
biometry alone with reduction in FPR from 27% to 16% for the same DR of about 71%25.  
 
Simultaneously to this study, colleagues from the same Departments have done a 
screening study of 30849 singleton pregnancies at 30-34 weeks’ gestation. Combined 
screening by maternal factors, fetal biometry, uterine artery PI and MAP at 30-34 weeks 
predicted 91% and 60% of SGA<5th neonates delivering at <5 and at >5 weeks of 
assessment, respectively, at FPR of 10%189.  
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Chapter 5: Screening by maternal characteristics, fetal biometry, placental 
growth factor and soluble fms-like tyrosine kinase-1 at 35-37 weeks 
 
ABSTRACT 
 
 
Objective: To investigate the potential value of maternal serum placental growth factor 
(PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) at 35-37 weeks’ gestation in the 
prediction of delivery of small for gestational age (SGA) neonates, in the absence of 
preeclampsia (PE).  
  
Methods: Screening study in singleton pregnancies at 35-37 weeks, including 158 that 
delivered SGA neonates with birth weight <5th percentile and 3,701 cases unaffected by 
SGA, PE or gestational hypertension. Multivariable logistic regression analysis was used 
to determine if serum PlGF and sFlt-1 improved the prediction of SGA neonates provided 
by screening with maternal characteristics and medical history (maternal factors), and 
estimated fetal weight (EFW) from fetal head circumference, abdominal circumference 
and femur length.  
  
Results: In the SGA group, compared to the normal group, the median PlGF multiple of 
the median (MoM) was significantly lower and the median sFlt-1 MoM was significantly 
higher. Combined screening by maternal factors and EFW Z-score at 35-37 weeks, 
predicted 90%, 92% and 94% of SGA neonates with birth weight <10th, <5th and <3rd 
percentiles delivering at <2 weeks of assessment, at 10% false positive rate; the 
respective values for SGA delivering at >37 weeks were 66.0%, 73% and 80%. When 
PlGF and sFlt-1 were added to a model that combines maternal factors and EFW Z-score, 
sFlt-1 did not remain as a significant independent predictor of SGA <5th. Combined 
screening by maternal factors, EFW Z-score and serum PlGF, predicted 88%, 96% and 
94% of SGA neonates with birth weight <10th, <5th and <3rd percentiles delivering at <2 
weeks of assessment and the respective values for SGA delivering at >37 weeks were 
64%, 75% and 80%.  
 
Conclusion: sFlt-1 does not provide significant independent prediction of SGA, in the 
absence of PE, in addition to combined testing by maternal factors and fetal biometry at 
35-37 weeks. Whilst addition of serum PlGF only marginally improves the performance of 
screening.  
 
This chapter is based on: Fadigas C, Peeva G, Mendez O, Poon LC and Nicolaides KH. 
Prediction of small-for-gestational age neonates: screening by placental growth factor and 
soluble fms-like tyrosine kinase-1 at 35-37 weeks. Ultrasound Obstet and Gynecol. 2015; 
46: 191-97. 
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5.1. INTRODUCTION 
 
The traditional approach of identifying pregnancies with SGA fetuses is maternal 
abdominal palpation and serial measurements of symphysial-fundal height, but the 
detection rate (DR) of this approach is less that 30%20, 21.  
 
Chapter 3 shows that a higher performance in screening for SGA is achieved by a 
combination of maternal characteristics and medical history (maternal factors) with EFW 
from ultrasonographic measurements of HC, AC and FL. Such combined screening at 35-
37 weeks, predicted 66%, 70% and 77% of SGA neonates with respective birth weight 
<10th, <5th and <3rd percentiles delivering at >37 weeks in the absence of preeclampsia 
(PE), at 10% false positive rate (FPR), The performance of screening was better for 
prediction of SGA delivering within two weeks of assessment with respective DRs of 88%, 
89% and 92%.  
 
Placental growth factor (PlGF) is a member of the vascular endothelial growth factor 
family and is implicated in angiogenesis and trophoblastic invasion of the maternal spiral 
arteries161-163. Soluble fms-like tyrosine kinase-1 (sFlt-1) is a circulating anti-angiogenic 
protein implicated in the pathogenesis of PE; the concentration of sFlt-1 is increased in 
the placenta and serum of women with PE and exogenous sFlt-1 administered to 
pregnant rats induces hypertension, proteinuria, and glomerular endotheliosis191. Several 
studies, mainly case-control, reported that in pregnancies delivering SGA neonates 
maternal serum PlGF is decreased and sFlt-1 is increased both in the second- and third-
trimesters of pregnancy 164-169.  
 
 
5.1.1. Objectives 
                                              
The objective of this study, in singleton pregnancies undergoing routine antenatal 
assessment at 35-37 weeks’ gestation, was to investigate the potential value of serum 
PlGF and sFlt-1 in improving the prediction of delivery of SGA neonates, in the absence of 
PE, achieved by the combination of maternal factors and EFW.  
 
 
5.2. METHODS 
 
The data for this study were derived from prospective screening for adverse obstetric 
outcomes in women attending for their routine hospital visit in the third trimester of 
pregnancy at 35+0-37+6 weeks’ gestation. The methodology for recording of patient 
characteristics, sonographic estimation of EFW, MAP, UtA IP, maternal serum metabolites 
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(PlGF and sFlt-1), outcome measures and statistical analysis was as described in Chapter 
2.  
 
 
5.3. RESULTS 
 
The characteristics of the study population of 3859 pregnancies, including 158 delivering 
SGA <5th neonates in the absence of PE, are presented in Table 5.1.  
 
Table 5.1. Characteristics of the study population of women with a singleton pregnancy with 
normal outcome or with a small-for-gestational-age (SGA) neonate, in the absence of pre-
eclampsia (PE) 
SLE = systemic lupus erythematosus; APS = antiphospholipid syndrome; IQR = interquartile range; PE = preeclampsia; 
SGA = small for gestational age 
 
 
Characteristic Normal 
(n=3701) 
SGA without PE 
(n=158) 
P-value 
Maternal age in years, median (IQR) 31.6 (26.9-35.2) 29.9 (24.2-35.3) 0.012 
Maternal weight in Kg, median (IQR) 78.8 (70.9-89.4) 72.7 (63.2-82.7) <0.0001 
Maternal height in cm, median (IQR) 164 (160-168) 161 (158-165) <0.0001 
Gestation at screening in weeks, median (IQR) 36.1 (36.0-36.4) 36.3 (36.0-36.4) 0.594 
Racial origin    
   Caucasian, n (%) 2762 (74.6) 95 (60.1) <0.0001 
   Afro-Caribbean, n (%) 615 (16.6) 38 (24.1) 0.022 
   South Asian, n (%) 132 (3.6) 16 (10.1) 0.0003 
   East Asian, n (%) 82 (2.2) 3 (1.9) >0.999 
   Mixed, n (%) 110 (3.0) 6 (3.8) 0.476 
Past obstetric history    
   Nulliparous, n (%) 1789 (48.3) 94 (59.5) 0.007 
   Parous with no prior PE and SGA, n (%) 1761 (47.6) 43 (27.2) <0.0001 
   Parous with prior PE no SGA, n (%) 59 (1.6) 0 (0.0) 0.175 
   Parous with prior SGA no PE, n (%) 86 (2.3) 20 (12.7) <0.0001 
   Parous with prior SGA and PE, n (%) 6 (0.2) 1 (0.6) 0.254 
Inter-pregnancy interval in years, median (IQR) 3.1 (2.1-5.0) 3.9 (2.1-6.2) 0.026 
Cigarette smoker, n (%) 325 (8.8) 37 (23.4) <0.0001 
Conception    
   Spontaneous, n (%) 3599 (97.2) 151 (95.6) 0.214 
   Ovulation drugs, n (%) 15 (0.4) 1 (0.6) 0.488 
   In vitro fertilization, n (%) 87 (2.4) 6 (3.8) 0.279 
Chronic hypertension 49 (1.3) 1 (0.6) 0.722 
Pre-existing diabetes mellitus, n (%) 43 (1.1) 1 (0.6) >0.999 
   Type 1, n (%) 20 (0.5) 1 (0.6) 0.585 
   Type 2, n (%) 23 (0.6) 0 (0.0) >0.999 
SLE / APS, n (%) 11 (0.3) 0 (0.0) >0.999 
Gestation at delivery in weeks, median (IQR) 40.0 (39.1-40.9) 39.6 (38.8-36.4) 0.002 
Birth weight in grams, median (IQR) 3450 (3,160-3,760) 2587 (2,350-
2,755) 
<0.0001 
Birth weight in percentile, median (IQR) 51.6 (27.4-76.2) 2.8 (1.2-3.7) <0.0001 
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5.3.1. Normal pregnancy outcome 
 
In the unaffected pregnancies with birth weight ≥5th percentile, the mean  SD, 5th and 10th 
percentiles of log10 MoM PlGF were -0.019  0.343, -0.588 and -0.470, respectively. The 
mean  SD, 90th and 95th percentiles of log10 MoM sFlt-1 were -0.081  0.210, 0.199 and 
0.285, respectively.  
 
There was a significant inverse association between log10 MoM values of PlGF and sFlt-1 
(r=-0.400, P<0.0001). There was a significant positive association between log10 MoM 
PlGF with assessment to delivery interval (r=0.152, P<0.0001) and birth weight Z-score 
(r=0.179, P<0.0001). There was a significant inverse association between log10 MoM  
sFlt-1 with assessment to delivery interval (r=-0.168, P<0.0001) and birth weight Z-score 
(r=-0.042, P=0.011).  
 
 
5.3.2. Small for gestational age  
 
In the SGA <5th group, compared to the normal group, the median MoM PlGF at 35-37 
weeks was significantly lower and the median MoM value of sFlt-1 was significantly higher 
(Table 5.2).  
 
 
Table 5.2. Placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) at 35-37 
weeks’ gestation in small for gestational age (SGA) neonates with birth weight below the 5th 
percentile, in the absence of preeclampsia and in the normal group. 
 
Biochemical 
markers 
pg/mL, 
Median (IQR) 
MoM, 
median (IQR) 
Log10 MoM, 
mean (SD) 
<5th (or >95th ) 
percentile, 
n (%, 95% CI) 
<10th (or >90th) 
percentile, 
n (%, 95% CI) 
Serum PlGF      
Normal 320.2 (181.2-576.6) 0.946 (0.548-1.654) -0.019 (0.343) 185 (5.0, 4.3-5.7) 370 (10.0, 9.1-11.0) 
SGA 195.6 (106.8-377.6)* 0.568 (0.301-0.933)* -0.228 (0.362)* 31 (19.6, 14.2-26.5)* 50 (31.6, 24.9-39.3)* 
Serum sFlt-1      
Normal 2,460.0 (1,831.0-3,447.5) 0.806 (0.598-1.122) -0.081 (0.210) 185 (5.0, 4.3-5.7) 370 (10.0, 9.1-11.0) 
SGA 2,908.5 (2,023.5-4,470.0)* 0.956 (0.654-1.435)* 0.005 (0.251)* 22 (13.9, 9.4-20.2)* 34 (21.5, 15.8-28.6)* 
 
Comparisons between pregnancies with normal outcome and those with SGA: Chi square test or 
Fisher’s exact test for categorical variables and Mann–Whitney U-test or student’s t-test: *P < 0.05. 
IQR, interquartile range; MoM, multiples of the unaffected median. 
 
 
 
There was a significant inverse association between log10 MoM values of PlGF and sFlt-1 
(r=-0.375, P<0.0001). There was a significant positive association between log10 MoM 
PlGF with assessment to delivery interval (r=0.300, P<0.0001; Figure 5.1.a) and birth 
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weight Z-score (r=0.208, P=0.009). There was a significant inverse association between 
log10 MoM sFlt-1 with assessment to delivery interval (r=-0.260, P=0.001; Figure 5.1.b) but 
not birth weight Z-score (r=-0.085, P=0.287).  
 
 
 
 
   (a)           (b) 
 
Figure 5.1. Log10 placental growth factor (a) and log10 soluble fms-like tyrosine kinase-1 (b) multiples of the 
median (MoM) according to assessment‐to‐delivery interval in pregnancies delivering small-for-gestational-
age neonates with birth weight < 5th percentile, plotted on the 50th (solid line) and 10th (dashed line) percentile 
of the normal range. 
 
 
Multivariable logistic regression analysis demonstrated that in the prediction of SGA <5th 
there were significant contributions from maternal characteristics and history, EFW Z-
score, and PlGF or sFlt-1 (Table 5.3). When PlGF and sFlt-1 were added to maternal 
factors and a model that combines maternal factors and EFW Z-score, sFlt-1 (P=0.509; 
R2=0.921) did not remain as a significant independent predictor of SGA <5th. Combined 
screening by maternal factors with EFW Z-scores and PlGF detected 64.1%, 75.3% and 
80.2% of SGA neonates with birth weight <10th, <5th and <3rd percentiles, respectively, at 
10% FPR.  
 
The areas under ROC (AUC), the detection rates (DRs) at FPRs of 5% and 10% and 
FPRs for DRs of 100%, 90% and 80% of SGA <10th, SGA <5th and SGA <3rd delivering at 
<2 weeks of assessment and at >37 weeks’ gestation when screening by maternal 
characteristics, EFW Z-score, PlGF and sFlt-1 are given in (Table 5.4, Table 5.5, Figure 
5.2 and Figure 5.3).  
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Table 5.3. Fitted regression models with maternal characteristics and history (maternal factors), 
estimated fetal weight (EFW) Z-score, placental growth factor (PlGF) and soluble fms-like tyrosine 
kinase-1 (sFlt-1) at 35–37 weeks’ gestation for the prediction of small-for-gestational-age neonates 
with birth weight < 5th percentile, in the absence of pre-eclampsia 
 
 
 
 
Independent variable Coefficient SE OR 95% CI P 
Maternal factors with PlGF (R2 = 0.182, P < 0.0001) 
Intercept –0.42984 0.27889 - - - 
Logit (a-priori risk) 2.38807 0.22459 10.892 7.014–16.916 < 0.0001 
Log10 MoM PlGF –2.06182 0.25619 0.127 0.077–0.210 < 0.0001 
Maternal factors with sFlt-1 (R2 = 0.136, P < 0.0001) 
Intercept –0.09724 0.26777 - - - 
Logit (a-priori risk) 2.49572 0.22265 12.130 7.841–18.767 < 0.0001 
Log10 MoM sFlt-1 0.92718 0.35454 2.527 1.261–5.064 0.009 
Log10 MoM sFlt-12 2.93094 1.08731 18.745 2.225–157.912 0.007 
Maternal factors, EFW and PlGF (R2 = 0.418, P < 0.0001) 
Intercept –2.10909 0.34712 - - - 
Logit (a-priori risk) 1.40611 0.25842 4.080 2.459–6.771 < 0.0001 
EFW Z-score –2.52481 0.17865 0.080 0.056–0.114 < 0.0001 
Log10 MoM PlGF –1.58096 0.28125 0.206 0.119–0.357 < 0.0001 
Maternal factors, EFW and sFlt-1 (R2 = 0.397, P < 0.0001) 
Intercept –1.80207 0.33685 - - - 
Logit (a-priori risk) 1.43451 0.25889 4.198 2.527–6.972 < 0.0001 
EFW Z-score –2.61927 0.17698 0.073 0.052–0.103 < 0.0001 
Log10 MoM sFlt-1 1.05551 0.41636 2.873 1.271–6.498 0.011 
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Table 5.4. Performance of screening for small-for-gestational-age (SGA) neonates with birth weight < 10th, < 5th and < 3rd percentile delivering within 2 weeks 
of assessment, in the absence of pre-eclampsia, using maternal characteristics and history, estimated fetal weight (EFW), placental growth factor (PlGF) and 
soluble fms-like tyrosine kinase-1 (sFlt-1) at 35–37 weeks’ gestation 
 
Screening test AUC DR (%) FPR (%) 
FPR 5% FPR 10% DR 100% DR 90% DR 80% 
SGA <10th percentile       
Maternal factors  0.818 (0.805-0.831) 30.6 (18.3-45.4) 53.1 (38.3-67.5) 77.6 (76.2-79.0) 47.1 (45.4-48.8) 34.9 (33.4-36.6) 
Maternal factors plus       
      EFW Z-score 0.965 (0.958-0.971) 83.7 (70.3-92.7) 89.8 (77.8-96.6) 53.4 (51.7-55.0) 10.8 (9.8-11.9) 3.0 (2.5-3.6) 
      PlGF 0.862 (0.850-0.873) 38.8 (25.2-53.8) 63.3 (48.3-76.6) 77.3 (75.9-78.7) 43.0 (41.4-44.7) 22.9 (21.5-24.4) 
      sFlt-1 0.836 (0.823-0.848) 38.8 (25.2-53.8) 53.1 (38.3-67.5) 76.3 (74.9-77.7) 44.2 (42.5-45.8) 28.0 (26.5-29.5) 
Maternal factors, EFW plus       
      PlGF 0.969 (0.963-0.974) 83.7 (70.3-92.7) 87.8 (75.2-95.4) 46.5 (44.9-48.2) 11.6 (10.5-12.7) 3.6 (3.0-4.3) 
      sFlt-1 0.967 (0.960-0.972) 83.7 (70.3-92.7) 87.8 (75.2-95.4) 50.5 (48.9-52.2) 12.5 (11.4-13.7) 2.8 (2.3-3.5) 
SGA <5th percentile       
Maternal factors  0.890 (0.879-0.900) 40.0 (21.1-61.3) 64.0 (42.5-82.0) 48.7 (47.0-50.3) 31.5 (30.0-33.1) 16.0 (14.9-17.2) 
Maternal factors plus       
      EFW Z-score 0.977 (0.972-0.982) 92.0 (74.0-99.0) 92.0 (74.0-99.0) 32.9 (31.3-34.4) 2.5 (2.0-3.0) 0.8 (0.5-1.1) 
      PlGF 0.944 (0.936-0.951) 56.0 (34.9-75.6) 84.0 (63.9-95.5) 19.0 (17.8-20.4) 16.6 (15.4-17.8) 9.8 (8.8-10.8) 
      sFlt-1 0.912 (0.902-0.921) 52.0 (31.3-72.2) 60.0 (38.7-78.9) 42.9 (41.3-44.5) 23.7 (22.3-25.1) 13.8 (12.7-14.9) 
Maternal factors, EFW plus       
      PlGF 0.987 (0.983-0.991) 88.0 (68.8-97.5) 96.0 (79.6-99.9) 13.9 (12.8-15.4) 5.2 (3.5-6.0) 0.3 (0.1-0.5) 
      sFlt-1 0.980 (0.975-0.984) 92.0 (74.0-99.0) 92.0 (74.0-99.0) 20.1 (18.8-21.4) 3.3 (2.8-4.0) 0.5 (0.3-0.8) 
SGA <3rd percentile       
Maternal factors  0.904 (0.894-0.913) 44.4 (21.5-69.2) 66.7 (41.0-86.7) 36.6 (35.1-38.2) 31.5 (30.0-33.1) 16.0 (14.9-17.2) 
Maternal factors plus       
      EFW Z-score 0.990 (0.987-0.993) 94.4 (72.7-99.9) 94.4 (72.7-99.9) 13.5 (12.5-14.7) 0.8 (0.5-1.1) 0.7 (0.4-1.0) 
      PlGF 0.948 (0.941-0.955) 61.1 (35.7-82.7) 83.3 (58.6-96.4) 19.0 (17.8-20.4) 16.6 (15.3-17.8) 9.8 (8.8-10.8) 
      sFlt-1 0.906 (0.896-0.915) 61.1 (35.7-82.7) 61.1 (35.7-82.7) 42.9 (41.3-44.5) 24.2 (22.9-25.7) 18.3 (17.1-19.6) 
Maternal factors, EFW plus       
      PlGF 0.991 (0.988-0.994) 94.4 (72.7-99.9) 94.4 (72.7-99.9) 13.9 (12.8-15.1) 0.3 (0.1-0.5) 0.2 (0.1-0.4) 
      sFlt-1 0.988 (0.984-0.991) 94.4 (72.7-99.9) 94.4 (72.7-99.9) 18.4 (17.2-19.7) 0.5 (0.3-0.8) 0.4 (0.2-0.7) 
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Table 5.5. Performance of screening for small for gestational age (SGA) neonates with birth weight <10th, <5th and <3rd percentile delivering at >37 weeks’ 
gestation in the absence of preeclampsia, with maternal characteristics and history, estimated fetal weight, placental growth factor (PlGF) and soluble fms-like 
tyrosine kinase-1 (sFlt-1) at 35-37 weeks’ gestation. 
 
 Screening test AUC DR (%) FPR (%) 
FPR 5% FPR 10% DR 100% DR 90% DR 80% 
SGA <10th percentile       
Maternal factors  0.730 (0.716-0.744) 21.3 (17.2-25.8) 34.6 (29.8-39.6) 99.9 (99.8-99.9) 68.0 (66.4-69.5) 48.7 (47.0-50.4) 
Maternal factors plus       
   EFW Z-score 0.888 (0.878-0.898) 47.3 (42.2-52.8) 66.0 (60.9-70.7) 82.2 (80.9-83.5) 32.2 (30.7-33.8) 19.8 (18.5-21.2) 
   PlGF 0.762 (0.748-0.775) 23.1 (19.0-27.7) 35.9 (31.1-41.0) 99.8 (99.6-99.9) 59.2 (57.6-60.9) 44.0 (42.4-45.7) 
   sFlt-1 0.731 (0.717-0.745) 20.0 (16.0-24.3) 33.0 (28.2-38.0) 99.6 (99.3-99.8) 67.2 (65.7-68.8) 47.6 (45.9-49.3) 
Maternal factors, EFW plus       
   PlGF 0.893 (0.883-0.903) 47.9 (42.7-53.1) 64.1 (59.0-68.9) 73.7 (72.2-75.2) 29.8 (28.3-31.4) 18.0 (16.7-19.3) 
   sFlt-1 0.886 (0.875-0.896) 48.1 (43.0-53.3) 63.8 (58.7-68.7) 81.9 (80.6-83.2) 32.5 (30.9-34.1) 20.4 (19.1-21.8) 
SGA <5th percentile       
Maternal factors  0.769 (0.756-0.782) 23.4 (16.9-30.9) 40.9 (33.1-49.1) 97.9 (97.3-98.3) 58.2 (56.6-59.8) 41.4 (39.8-43.0) 
Maternal factors plus       
   EFW Z-score 0.918 (0.909-0.926) 53.9 (45.7-61.9) 72.7 (65.0-79.6) 79.1 (77.7-80.4) 19.9 (18.7-21.3) 12.2 (11.2-13.3) 
   PlGF 0.807 (0.794-0.819) 26.6 (19.8-34.3) 44.2 (36.2-52.4) 98.6 (98.2-98.9) 51.5 (49.8-53.1) 32.5 (31.0-34.0) 
   sFlt-1 0.769 (0.756-0.783) 25.3 (18.7-33.0) 38.3 (30.6-46.5) 96.1 (95.4-96.7) 60.5 (59.0-62.1) 42.9 (41.3-44.5) 
Maternal factors, EFW plus       
   PlGF 0.922 (0.913-0.930) 56.5 (48.3-64.5) 74.7 (67.0-81.0) 75.3 (73.9-76.7) 21.4 (20.1-22.8) 13.8 (12.7-15.0) 
   sFlt-1 0.918 (0.909-0.927) 53.9 (45.7-61.9) 74.7 (67.0-81.0) 81.0 (79.7-82.3) 20.4 (19.1-21.7) 13.1 (12.0-14.2) 
SGA <3rd percentile       
Maternal factors  0.806 (0.793-0.818) 28.6 (19.2-39.5) 46.4 (35.5-57.6) 90.2 (89.2-91.1) 47.3 (45.6-48.9) 38.0 (36.4-39.6) 
Maternal factors plus       
   EFW Z-score 0.942 (0.934-0.949) 63.1 (51.9-73.4) 79.8 (69.6-87.7) 42.9 (41.3-44.5) 13.9 (12.8-15.1) 10.9 (9.9-11.9) 
   PlGF 0.828 (0.816-0.840) 32.1 (22.4-43.2) 53.6 (42.4-64.5) 84.8 (83.6-86.0) 51.5 (49.9-53.1) 29.9 (28.4-31.4) 
   sFlt-1 0.803 (0.790-0.816) 32.1 (22.4-42.0) 44.1 (33.2-55.3) 91.8 (90.9-92.7) 49.4 (47.8-51.0) 40.1 (38.6-41.8) 
Maternal factors, EFW plus       
   PlGF 0.943 (0.935-0.950) 65.5 (54.3-75.5) 79.8 (69.6-87.7) 41.1 (39.6-42.8) 16.1 (15.0-17.4) 11.7 (10.7-12.8) 
   sFlt-1 0.942 (0.934-0.949) 60.7 (49.5-71.2) 79.8 (69.6-87.7) 40.8 (39.2-42.4) 16.2 (15.0-17.4) 10.8 (9.9-11.9) 
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          (a. <10th)         (b. <5th)          (c. <3rd) 
Figure 5.2. Receiver–operating characteristics curves of maternal factors (black line), maternal 
factors with estimated fetal weight (EFW) (blue line), maternal factors with EFW and placental 
growth factor (red line) at 35–37 weeks' gestation, in the prediction of small-for-gestational-age 
neonates with birth weight < 10th (a), < 5th (b) and < 3rd (c) percentile, delivering within 2 weeks of 
assessment. 
 
 
 
          (a. <10th)         (b. <5th)          (c. <3rd) 
Figure 5.3. Receiver–operating characteristics curves of maternal factors (black line), maternal 
factors with EFW (blue line), maternal factors with EFW and placental growth factor (red line) at 
35–37 weeks' gestation, in the prediction of small-for-gestational-age neonates with birth 
weight < 10th (a), < 5th (b) and < 3rd (c) percentile, delivering ≥ 37 weeks' gestation. 
 
 
The DRs, at FPR of 10%, of combined screening by maternal factors with EFW Z-scores 
for the prediction of SGA neonates with birth weight <10th, <5th and <3rd percentiles, 
delivering at <2 weeks of assessment, were 89.8% (95% CI, 77.8-96.6; AUC 0.965 (95% 
CI, 0.958-0.971)), 92.0% (95% CI, 74.0-99.0 AUC 0.977 (95% CI, 0.972-0.982)) and 
94.4% (95% CI, 72.7-99.9; AUC 0.990 (95% CI, 0.987-0.993)), respectively. The 
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respective values for SGA delivering at >37 weeks, were 66.0% (95% CI, 60.9-70.7; AUC 
0.888 (95% CI, 0.878-0.898)), 72.7% (95% CI, 65.0-79.6; AUC 0.918 (95% CI, 0.909-
0.926)) and 79.8% (95% CI, 69.6-87.7; AUC 0.942 (95% CI, 0.934-0.949)).  
 
In combined screening by maternal factors with EFW Z-scores and serum PlGF at 35-37 
weeks’ gestation, the DRs, at FPR of 10%, of SGA neonates with birth weight <10th, <5th 
and <3rd percentiles delivering at <2 weeks of assessment were 87.8% (95% CI, 75.2-
95.4; AUC 0.969 (95% CI, 0.963-0.974)), 96.0% (95% CI, 79.6-99.9; AUC 0.987 (95% CI, 
0.983-0.991)) and 94.4% (95% CI, 72.7-99.9; AUC 0.991 (95% CI, 0.988-0.994)). The 
respective values for SGA delivering at >37 weeks, were 64.1% (95% CI, 59.0-68.9; AUC 
0.893 (95% CI; 0.883-0.903)), 74.7% (95% CI, 67.0-81.0; AUC 0.922 (95% CI, 0.913-
0.930)) and 79.8% (95% CI, 69.6-87.7; AUC 0.943  (95% CI, 0.935-0.950)).  
 
 
5.4. DISCUSSION 
 
5.4.1. Main findings of the study 
 
The findings of this study demonstrate that at 35-37 weeks’ gestation, in pregnancies that 
deliver SGA neonates in the absence of PE maternal serum PlGF is reduced and sFlt-1 is 
increased. The alterations in serum biochemistry are more pronounced in those with 
severe disease reflected at lower birth weight (3rd vs. 10th percentile) and delivery within 
two weeks from assessment.  
 
Combined screening by maternal factors and EFW Z-score at 35-37 weeks, predicted 
90%, 92% and 94% of SGA neonates with birth weight <10th, <5th and <3rd percentiles 
delivering at <2 weeks of assessment, at FPR of 10%; the respective values for SGA 
delivering at >37 weeks were 66%, 73% and 80%. Combined screening by maternal 
factors, EFW Z-score and serum PlGF, predicted 88%, 96% and 94% of SGA neonates 
with birth weight <10th, <5th and <3rd percentiles delivering at <2 weeks of assessment and 
the respective values for SGA delivering at >37 weeks were 64%, 75% and 80%. 
Consequently, addition of serum PlGF only marginally improves the screening 
performance for the delivery of SGA neonates, in the absence of PE, achieved by 
maternal factors and fetal biometry alone. 
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5.4.2. Comparison with findings from previous studies 
 
Most previous reports on maternal serum PlGF and sFlt-1 in pregnancies with SGA 
fetuses / neonates were based on case-control studies involving a small number of 
affected pregnancies164-169. Such studies compared the median serum concentration of 
the angiogenic and anti-angiogenic factors or their ratio in affected and unaffected 
pregnancies or the percentage of cases above or below certain concentration cut-offs. 
Our study involved screening of all pregnancies attending for a routine scan at 35-37 
weeks and assessed the value of serum PlGF and sFlt-1 both individually and in 
combination with maternal factors and fetal biometry in screening for SGA delivering at 
term in the absence of PE.  
 
The advantage of using Bayes theorem to combine the prior risk from maternal 
characteristics and medical history, fetal biometry and biomarkers is that individual patient 
risks can be estimated for any predefined severity of SGA and any interval from testing to 
delivery. This is an essential first step for the establishment of patient management 
protocols.  
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Chapter 6: Conclusion 
 
 
6.1. SUMMARY OF RESULTS 
 
This study has shown that combined screening by maternal factors and EFW Z-score at 
35-37 weeks, predicted 90%, 92% and 94% of SGA neonates with birth weight <10th, <5th 
and <3rd percentiles delivering at <2 weeks of assessment, at 10% false positive rate; the 
respective values for SGA delivering at >37 weeks were 66%, 73% and 80%.  
 
Addition of UtA PI and MAP to combined testing using maternal factors and fetal biometry 
at 35-37 weeks has not improved the performance of screening. 
 
When PlGF and sFlt-1 were both added to a model that combines maternal factors and 
EFW Z-score, sFlt-1 did not remain as a significant independent predictor of SGA <5th. 
Combined screening by maternal factors, EFW Z-score and serum PlGF, predicted 88%, 
96% and 94% of SGA neonates with birth weight <10th, <5th and <3rd percentiles delivering 
at <2 weeks of assessment and the respective values for SGA delivering at >37 weeks 
were 64%, 75% and 80%.  Hence, addition of serum PlGF only marginally improves the 
performance of screening.  
 
Such performance of screening is superior to that achieved by the current method in the 
UK, which is based on maternal characteristics and measurement of SFH21.  
 
 
6.2. STRENGTHS AND LIMITATIONS 
 
This study has several strengths. Firstly, this was the largest routine screening study 
carried out at 35-37 weeks, a gestational age when there was few literature regarding 
assessing fetal growth and wellbeing. Secondly, the study ensured that only appropriately 
trained doctors, certified by the Fetal Medicine Foundation, using specific methodology 
undertook the measurements of HC, AC FL, MAP and uterine artery PI. Thirdly, it 
assessed two biochemical markers (PlGF and sFlt-1), which have been associated with 
impaired placentation at late third trimester. Fourthly, the study used Bayes theorem to 
combine the prior risk from maternal characteristics and medical history with biomarkers, 
to estimate patient-specific risks and the performance of screening for SGA of different 
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severities delivering at selected intervals from the time of assessment, which is an 
essential step for establishing patient management protocols. 
 
The main limitation of the study is that the patient's obstetricians were made aware of the 
screening results. This would have led to further monitoring of identified SGA fetuses and 
possible delivery. Such intervention would positively bias the performance of screening, 
particularly those delivering within 2 weeks of assessment.  
 
 
 
6.3. IMPLICATIONS FOR CLINICAL PRACTICE 
 
This study has the potential to influence clinical practice. Since completion of the studies 
in this thesis, colleagues from the same department have examined the potential value of 
screening for SGA neonates at 30-34 weeks’ gestation. They compared screening at 30-
34 weeks, also with biophysical and biochemical markers, namely, maternal factors, EFW, 
UtA PI, MAP and the PlGF (sFlt-1 was not included, as the use of PlGF alone was better 
predictor than PlGF and sFlt-1). The DRs, at a FPR of 10%, of SGA neonates with BW 
<10th, <5th and<3rd percentiles delivering ≥37 weeks were 57%, 65%, 71%192 compared 
with our study's results of 64%, 75%, and 80%. Thus, the 35-37 weeks scan performed 
better for detection of SGA ≥ 37 weeks. 
 
In the proposed new pyramid of pregnancy care193, an integrated clinic at 11-13 weeks’ 
gestation, in which biophysical and biochemical markers are combined with maternal 
characteristics and medical history, aims to identify pregnancies at high-risk of developing 
PE and/or SGA137, 194 and through pharmacological intervention (eg, aspirin) to reduce the 
prevalence of these complications195-198. 
 
The objective of subsequent visits, at around 22 and 32 or 36 weeks’ gestation, are to 
identify the high-risk group and through close monitoring of such pregnancies to minimize 
adverse perinatal events by determining the appropriate time and place for iatrogenic 
delivery. It was proposed that all women should be offered a third-trimester scan for 
assessment of fetal growth and wellbeing and that the timing of such scan, at 32 and/or 
36 weeks, should be contingent on the results of assessment at around 22 weeks187-188,199. 
 
The 19-24 gestational weeks' model, simultaneously proposed by colleagues of the same 
Department199, uses maternal factors, fetal biometry, UtA-PI and serum PlGF and AFP as 
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significant independent contributions to the prediction of SGA (< 5th percentile). The 
detection rate (DR) of such combined screening at 19-24 weeks was 100%, 78% and 42% 
for SGA (< 5th percentile) delivering < 32, at 32-36 and ≥ 37 weeks' gestation, respectively, 
at a false-positive rate (FPR) of 10%. In a hypothetical model, it was estimated that if the 
desired objective of prenatal screening is to predict about 80% of the cases of SGA < 5th, 
at a FPR of 10%, it would be necessary to select 11% of the population at the 19-24-week 
assessment to be reassessed at 32 weeks and 44% to be reassessed at 36 weeks; 57% 
would not require a third-trimester scan. 
 
Following a 35-37 weeks scan, on the basis of results from this thesis study, if the 
assessment includes a combination of maternal factors, fetal biometry and serum PlGF, 
potentially 80%, 90% and 100% of cases of SGA <5th without PE could be detected at 
respective FPRs of 14%, 21% and 75%. The subsequent management of the screen 
positive group with the objective of reducing perinatal death and handicap remains to be 
determined. 
 
Regarding the timing of the 35-37 weeks routine appointment, which up until the 
publication of the studies of this thesis there was very scarce information on, it can also be 
useful, not only to predict SGA without PE, but also to predict term pre-eclampsia. 
Colleagues from the same department200 developed a model for prediction of term pre-
eclampsia (PE) based on a combination of maternal factors and late third-trimester 
biomarkers. Screening for term PE by a combination of maternal factors, MAP, PlGF and 
sFlt‐1 at 35–37 weeks' gestation predicted about 85% of affected pregnancies, at a FPR 
of 10%. Hence, the screening performance at 35-37 weeks for late PE is also superior to 
that achieved by screening at 11–13, 19–24 or 30–34 weeks, with respective DRs of 47%, 
46% and 66%. 
 
Since the publication and presentation of the data in this thesis, late third trimester routine 
growth scans have been progressively implemented and further studies have been being 
pursued in this field.  
 
 
 
6.4. FUTURE STUDIES 
 
The proposed model from this thesis for prediction of SGA neonates requires prospective 
intervention studies that would firstly, evaluate the predicted performance of such 
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screening and secondly, examine the extent to which such assessment and appropriate 
management of the high-risk pregnancies can reduce the high perinatal mortality and 
morbidity associated with SGA fetuses. 
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Appendix A.1. Paper "Prediction of small-for-gestational-age neonates: screening 
by fetal biometry at 35-37 weeks", published in Ultrasound in Obstetrics & Gynecology, 
May 2015. 
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Appendix A.2. Paper "Prediction of small-for-gestational-age neonates: screening 
by uterine artery Doppler and mean arterial pressure at 35-37 weeks", published in 
Ultrasound in Obstetrics & Gynecology, June 2015. 
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Appendix A.3. Paper "Prediction of small-for-gestational-age neonates: screening 
by placental growth factor and soluble fms-like tyrosine kinase-1 at 35-37 weeks", 
published in Ultrasound in Obstetrics & Gynecology, August 2015. 
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